US20140142445A1 - Vital sign monitor for cufflessly measuring blood pressure using a pulse transit time corrected for vascular index - Google Patents

Vital sign monitor for cufflessly measuring blood pressure using a pulse transit time corrected for vascular index Download PDF

Info

Publication number
US20140142445A1
US20140142445A1 US14/072,305 US201314072305A US2014142445A1 US 20140142445 A1 US20140142445 A1 US 20140142445A1 US 201314072305 A US201314072305 A US 201314072305A US 2014142445 A1 US2014142445 A1 US 2014142445A1
Authority
US
United States
Prior art keywords
blood pressure
pressure
patient
dependent
ptt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/072,305
Inventor
Matthew J. Banet
Marshal Singh Dhillon
Andrew Stanley Terry
Zhou Zhou
II Henk VISSER
Robert J. Kopotic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sotera Wireless Inc
Original Assignee
Sotera Wireless Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sotera Wireless Inc filed Critical Sotera Wireless Inc
Priority to US14/072,305 priority Critical patent/US20140142445A1/en
Publication of US20140142445A1 publication Critical patent/US20140142445A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/02Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
    • A61B5/021Measuring pressure in heart or blood vessels
    • A61B5/02108Measuring pressure in heart or blood vessels from analysis of pulse wave characteristics
    • A61B5/02125Measuring pressure in heart or blood vessels from analysis of pulse wave characteristics of pulse wave propagation time
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/02Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
    • A61B5/02007Evaluating blood vessel condition, e.g. elasticity, compliance
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/02Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
    • A61B5/021Measuring pressure in heart or blood vessels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/02Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
    • A61B5/026Measuring blood flow
    • A61B5/0285Measuring or recording phase velocity of blood waves
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/74Details of notification to user or communication with user or patient ; user input means
    • A61B5/7475User input or interface means, e.g. keyboard, pointing device, joystick
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B2562/00Details of sensors; Constructional details of sensor housings or probes; Accessories for sensors
    • A61B2562/08Sensors provided with means for identification, e.g. barcodes or memory chips
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/24Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
    • A61B5/316Modalities, i.e. specific diagnostic methods
    • A61B5/318Heart-related electrical modalities, e.g. electrocardiography [ECG]
    • A61B5/346Analysis of electrocardiograms
    • A61B5/349Detecting specific parameters of the electrocardiograph cycle
    • A61B5/352Detecting R peaks, e.g. for synchronising diagnostic apparatus; Estimating R-R interval
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/72Signal processing specially adapted for physiological signals or for diagnostic purposes
    • A61B5/7235Details of waveform analysis
    • A61B5/7239Details of waveform analysis using differentiation including higher order derivatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/72Signal processing specially adapted for physiological signals or for diagnostic purposes
    • A61B5/7235Details of waveform analysis
    • A61B5/7253Details of waveform analysis characterised by using transforms
    • A61B5/7257Details of waveform analysis characterised by using transforms using Fourier transforms

Definitions

  • the present invention generally relates to medical devices for monitoring vital signs, e.g., arterial blood pressure.
  • Pulse transit time (PTT), defined as the transit time for a pressure pulse launched by a heartbeat in a patient's arterial system, has been shown in a number of studies to correlate to both systolic and diastolic blood pressure. In these studies, PTT is typically measured with a conventional vital sips monitor that includes separate modules to determine both an electrocardiogram (ECG) and pulse oximetry. During a PTT measurement, multiple electrodes typically attach to a patient's chest to determine a time-dependent ECG component characterized by a sharp spike called the ‘QRS complex’. This feature indicates an initial depolarization of ventricles within the heart and, informally, marks the beginning of the heartbeat and a pressure pulse that follows.
  • ECG electrocardiogram
  • QRS complex time-dependent ECG component characterized by a sharp spike
  • Pulse oximetry is typically measured with a bandage or clothespin-shaped sensor that attaches to a patient's finger, and includes optical systems operating in both the red and infrared spectral regions.
  • a photodetector measures radiation emitted from the optical systems and transmitted through the patient's finger.
  • Other body sites e.g., the ear, forehead, and nose, can also be used in place of the finger.
  • a microprocessor analyses both red and infrared radiation measured by the photodetector to determine the patient's blood oxygen saturation level and a time-dependent waveform called an optical waveform or plethysmograph. Time-dependent features of the optical waveform indicate both pulse rate and a volumetric absorbance change in an underlying artery (e.g., in the finger) caused by the propagating pressure pulse.
  • Typical PTT measurements determine the time separating a maximum point on the QRS complex (indicating the peak of ventricular depolarization) and a foot of the optical waveform (indicating the beginning the pressure pulse).
  • PTT depends primarily on arterial compliance, the propagation distance of the pressure pulse (closely approximated by the patient's arm length), and blood pressure.
  • PTT-based measurements of blood pressure are typically ‘calibrated’ using a conventional blood pressure cuff.
  • the blood pressure cuff is applied to the patient, used to make one or more blood pressure measurements, and then removed. Going forward, the calibration blood pressure measurements are used, along with a change in PTT, to estimate the patient's blood pressure and blood pressure variability.
  • PTT typically relates inversely to blood pressure, i.e., a decrease in PTT indicates an increase in blood pressure.
  • U.S. Pat. Nos. 5,316,008; 5,857,975; 5,865,755; and 5,649,543 each describe an apparatus that includes conventional sensors that measure an ECG and optical waveform, which are then processed to determine PTT.
  • Embodiments described herein provide a medical device that makes a cuffless measurement of blood pressure using PTT and a correction that accounts for the patient's arterial properties (e.g., stiffness and size).
  • This correction referred to herein as a ‘vascular index’ (‘VP’)
  • VP vascular index
  • a patient's arteries typically stiffen with age, and thus biological age provides an initial estimate arterial stiffness.
  • VI is used along with biological age to further improve the accuracy of PTT-calculated blood pressure, as it serves as a proxy for a ‘true’ age of the patient's vasculature: patients with elastic arteries for their age will have a VI less than their biological age. While patients with stiff arteries for their age will have a VI greater than their biological age. VI, as used in this application, has the units of years.
  • an optical waveform yields a VI after it is passed through digital filters and processed with a series of mathematical algorithms.
  • the digital filters are implemented using Fast Fourier Transforms (‘FFT’, also referred to herein as a ‘Windowed-Sine Digital Filter’).
  • FFT Fast Fourier Transforms
  • the VI is used in combination with the patient's biological age to estimate their arterial properties. These properties are then used to ‘correct’ the blood pressure determination that was determined by the PTT and thus calculate blood pressure without the need for an external calibration (e.g., without input of an external blood pressure measurement., e.g. an auscultatory or oscillometric measurement).
  • Embodiments described herein are based on the realization that a. PTT-based blood pressure measurement, corrected for the patient's arterial properties using age and VI, shows a better correlation to actual blood pressure than one that is based on PTT alone. Moreover, the correlation between PTT and blood pressure is further improved by measuring PTT using ECG (referred to herein as an ‘electrical waveform’) and an optical waveform measured near the patient's brachial artery (i.e., near the patient's elbow, superior to the medial epicondyle) or radial artery (e.g., the common site for feeling a pulse near the patient's wrist). Due to the thickness of tissue in these regions, the optical waveform is best measured using a reflective optical sensor.
  • ECG ECG
  • an optical waveform measured near the patient's brachial artery
  • radial artery e.g., the common site for feeling a pulse near the patient's wrist
  • the signal-to-noise ratio of the waveform can be increased by using a multi-sensor array instead of a single sensor, and by choosing an optical wavelength ( ⁇ ⁇ 570 nm) that works well in reflection-mode geometry for a variety of skin pigmentations. This wavelength may vary slightly (i.e. from 560-580 nm) without affecting the measurement.
  • the above-described method for calculating blood pressure using PTT and a correction derived from VI can be used in a ‘composite’ blood pressure measurement technique featuring both pressure-dependent and pressure-free components.
  • the composite technique determines blood pressure using: 1) a first, pressure-dependent step that analyzes both PTT and the amplitude of the optical waveform while pressure is applied to the patient's brachial artery; and 2) a second, pressure-free measurement of PTT and information from the pressure-dependent measurement in routine clinical use, the pressure-free approach typically makes up about 95% of the composite technique's total measurements; pressure-dependent measurements are typically used to calibrate the device and to correct any time-dependent drift in the pressure-free measurements.
  • Drill may occur, for example, due to changes in the patient's temperature, arterial tone and compliance, or cardiac pre-injection period. Both the pressure-dependent and pressure-free measurements use the same measurement system, which features both optical and electrical sensors to measure PTT.
  • the composite technique accurately and continuously determines the patient's blood pressure over an extended time without requiring an external calibration device, e.g., an external blood pressure cuff.
  • the composite technique is also based on the discovery that PTT, measured in the presence of an applied pressure, typically increases when the applied pressure is equal to or greater than the patient's diastolic blood pressure. As the applied pressure gradually increases to the patient's systolic pressure, PTT continues to increase, typically in a linear manner. When the applied pressure equals systolic blood pressure, the amplitude of an optical waveform measured below the region of applied pressure decreases to zero, and the PTT is no longer measurable. Thus, analyzing both PTT and the optical waveform's amplitude over a suitable range yields the patient's systolic blood pressure. Further analysis of the pressure-dependent increase in PTT yields a calibration that relates PTT and blood pressure for the particular patient. Once determined, these parameters are used with a PTT measured with the same optical and electrical sensors (but no applied pressure) to continuously measure the patient's blood pressure.
  • PTT, VI and blood pressure are analyzed with a hand-held device that includes many features of a conventional personal digital assistant (PDA).
  • PDA personal digital assistant
  • the device includes, for example, a microprocessor that runs an icon-driven graphical user interface (GUI) on a color, liquid crystal display attached to a touch panel.
  • GUI graphical user interface
  • a user selects different measurement modes, such as continuous measurements in the hospital, one-time measurements at home and in the hospital, and 24-hour ambulatory measurements, by tapping a stylus on an appropriate icon within the GUI.
  • the device also includes several other hardware features commonly found in PDAs, such as short-range (e.g., Bluetooth® and WiFi® and long-range (e.g., CDMA, GSM, IDEN) modems, global positioning system, digital camera, and barcode scanner.
  • short-range e.g., Bluetooth® and WiFi®
  • long-range e.g., CDMA, GSM, IDEN
  • global positioning system e.g., GPS, digital camera, and barcode scanner.
  • the described embodiment provides a method for measuring a patient's blood pressure that includes: 1) measuring a time-dependent optical waveform with an optical sensor; 2) measuring a time-dependent electrical waveform with an electrical sensor; 3) determining a VI from the time-dependent optical waveform; 4) determining a PTT from the time-dependent electrical signal from the heart and the time-dependent optical waveform; 5) calculating a blood pressure value using a mathematical model that includes PTT and a predetermined relationship between PTT and blood pressure; and 6) correcting the blood pressure with the VI and the patient's biological age.
  • the method includes determining the VI by analyzing the properties (e.g., taken from the second derivative) of the first optical waveform.
  • the optical sensor typically operates in a transmission or reflection-mode geometry near the patient's brachial, radial or ulnar arteries.
  • 3 electrodes disposed on the patient in a conventional ‘Einthoven's triangle’ configuration, detect electrical signals which, once processed, determine the electrical waveform.
  • the device described herein uses both PTT and VI to make a continuous, cuffless measurement of blood pressure. This allows, for example, patients to be better monitored in hospitals and medical clinics. Moreover, the device combines all the data-analysis features and form factor of a conventional PDA with the monitoring capabilities of a conventional vital sign monitor. This results in an easy-to-use, flexible device that performs one-time, continuous, and ambulatory measurements both in and outside of a hospital. Moreover, the optical and electrical sensors can be connected to a comfortable, lightweight body sensor that wirelessly communicates with monitor. This eliminates the wires that normally tether a patient to a conventional vital sign monitor, thereby increasing patient comfort and enabling mobility.
  • FIG. 1 is a top view of a circuit board used in the body sensor.
  • FIG. 2 is a three-dimensional plan view of the monitor.
  • FIG. 3 shows an abstraction of a mathematical equation describing how blood pressure can be calculated from PTT and VI.
  • FIGS. 4A , 4 C, and 4 E are graphs of, respectively, a first fixed-frequency handpass filter, a second fixed-frequency bandpass filter, and an adaptive handpass filter used during waveform analysis.
  • FIG. 4B is a graph of a second derivative of the optical waveform after filtering with the first fixed-frequency bandpass filter of FIG. 4A ,
  • FIG. 4D is a graph of a second derivative of the optical waveform after filtering with the second fixed-frequency bandpass filter of FIG. 4C .
  • FIG. 4F is a graph of a second derivative of the optical waveform after filtering with the second fixed-frequency and adaptive-frequency bandpass filters of, respectively, FIGS. 4C and 4E .
  • FIG. 5 is a graph of an error in systolic blood pressure vs. the difference between VI and age for a 200-patient study.
  • FIGS. 6A and 6B are graphs showing the correlation of systolic blood pressure measured with a cuff vs. systolic blood pressure measured according to the approach described herein determined, respectively, before and after the VI correction.
  • FIG. 7 is a flow chart showing an algorithm used to measure blood pressure by analyzing PTT and VI.
  • FIGS. 8A and 8B show, respectively, schematic drawings of pressure-free and pressure-dependent measurements used in the composite technique.
  • FIG. 9 shows a schematic drawing of a patient and optical and electrical waveforms measured during the pressure-dependent and pressure-free measurements of FIGS. 8A and 8B .
  • FIG. 10 shows graphs of time-dependent pressure, optical, and electrical waveforms measured with the body sensor and the optical, electrical, and pressure sensors.
  • FIGS. 11A and 11B show graphs of, respectively, PTT and the amplitude of the optical waveform as a function of pressure.
  • FIGS. 1 and 2 show a system featuring a body sensor and monitor that performs a PTT-based blood pressure measurement, corrected for VI, on a patient.
  • the blood pressure measurement features pressure-dependent and pressure-free measurements.
  • the system measures: i) an optical waveform from the patient with an optical sensor; ii) an electrical waveform using an electrical sensor featuring multiple ECG electrodes; and iii) a pressure waveform using armband featuring an inflatable bladder.
  • a first algorithm operating on the body sensor described in detail below, analyzes the optical waveform to estimate VI.
  • a second algorithm calculates PTT from the electrical and optical waveforms, and uses this value to calculate blood pressure. VI and biological age are then compared to a predetermined correction factor aid used adjust the PTT-determined blood pressure value.
  • FIG. 1 shows a top view of the body sensor 1 used to conduct the above-described measurements.
  • the body sensor 1 features a single circuit board 12 including connectors 5 , 15 that connect through separate cables 19 , 21 to, respectively, the electrical sensor (electrodes worn on the patient's chest) and optical sensor (worn on the patient's wrist).
  • the electrical sensor electrodelectrodes worn on the patient's chest
  • optical sensor worn on the patient's wrist.
  • these sensors measure electrical and optical signals that pass through the connectors 5 , 15 to discrete circuit components 11 on the bottom side of the circuit board 12 .
  • the discrete components 11 include: i) analog circuitry for amplifying and filtering the time-dependent optical and electrical waveforms; ii) an analog-to-digital converter for converting the time-dependent analog signals into digital waveforms; and iii) a microprocessor for processing the digital waveforms to determine blood pressure according to the composite technique, along with other vital signs.
  • the circuit board 12 additionally includes a small mechanical pump 4 for inflating the bladder within the armband, and first and second solenoid values 3 a , 3 b for controlling the bladder's inflation and deflation rates.
  • the pump 4 and solenoid valves 3 a , 3 b connect through a manifold 7 to a connector 10 that attaches through a tube (not shown in the figure) to the bladder in the armband, and additionally to a digital pressure sensor 16 that senses the pressure in the bladder.
  • the first solenoid valve 3 a couples through the manifold 7 to a small ‘bleeder’ valve 17 featuring a small hole that slowly releases pressure.
  • the second solenoid valve 3 b is coupled through the manifold 7 and rapidly releases pressure.
  • both solenoid valves 3 a , 3 b are closed as the pump 4 inflates the bladder.
  • pulsations caused by the patient's heartbeats couple into the bladder as it inflates, and are mapped onto the pressure waveform.
  • the digital pressure sensor 16 generates an analog pressure waveform, which is then digitized with the analog-to-digital converter described above.
  • the microprocessor processes the digitized pressure, optical, and electrical waveforms to deter mine systolic, mean arterial, and diastolic blood pressures. Once these measurements are complete, the microprocessor immediately opens the second solenoid valve 3 b , causing the bladder to rapidly deflate.
  • the pump 4 inflates the bladder to a pre-programmed pressure above the patient's systolic pressure. Once this pressure is reached, the microprocessor opens the first solenoid valve 3 a , which couples to the ‘bleeder’ valve 17 to slowly release the pressure. During this deflation period, pulsations caused by the patient's heartbeat are coupled into the bladder and are mapped onto the pressure waveform, which is then measured by the digital pressure sensor 16 . Once the microprocessor determines systolic, mean arterial, and diastolic blood pressure, it opens the second solenoid valve 3 b to rapidly evacuate the pressure.
  • the board 12 additionally includes a plug 6 which accepts power from a wall-mounted AC adaptor.
  • the AC adaptor is used, for example, when measurements are made over an extended period of time
  • a rugged plastic housing (not shown in the figure) covers the circuit board 12 and all its components.
  • a Bluetooth transmitter 23 is mounted directly on the circuit board 12 and, following a measurement, wirelessly transmits information to an external monitor.
  • the optical modules within the optical sensor typically include an LED operating near 570 nm, a photodetector, and an amplifier. This wavelength is selected because, when deployed in a reflection-mode geometry, it is particularly sensitive to volumetric absorbance changes in an underlying artery for a wide variety of skin pigmentations.
  • a preferred sensor is described in the following co-pending patent application, the entire contents of which are incorporated herein by reference: SYSTEM FOR MEASURING VITAL SIGNS USING AN OPTICAL MODULE FEATURING A GREEN LIGHT SOURCE (U.S. Ser. No. 11/307,375; filed Feb. 3, 2006).
  • multiple optical modules are used in the sensor to increase the probability that an underlying (or proximal) artery is measured, thus increasing the signal-to-noise ratio of the measurement.
  • the multiple sensors collectively measure an optical waveform that includes photocurrent generated by each optical module.
  • the resultant signal forms the optical waveform, and effectively represents an ‘average’ signal measured from vasculature (e.g., arteries, arterioles and capillaries) underneath the sensor.
  • the optical sensor can additionally include LEDs operating near 650 nm and 950 nm in order to make a pulse oximetry measurement.
  • FIG. 2 shows a three-dimensional plan view of the monitor 50 that receives the Bluetooth-transmitted information.
  • the front face of the monitor 50 includes a touchpanel display 55 that renders an icon-driven graphical user interface, and a circular on/off button 59 .
  • the touchpanel display 55 renders vital sip information from the body sensor.
  • BLOOD PRESSURE MONITOR U.S. Ser. No. 11/530,076; filed Sep. 8, 2006
  • MONITOR FOR MEASURING VITAL SIGNS AND RENDER [NO VIDEO IMAGES U.S. Ser. No. 11/682,177; filed Mar. 5, 2007
  • the monitor 50 includes an internal Bluetooth transmitter (not shown in the figure) that can include an antenna 60 to increase the strength of the received signal.
  • the monitor 50 includes a barcode scanner 57 on its top surface.
  • a user holds the monitor 50 in one hand, and points the barcode scanner 57 at a printed barcode adhered to the plastic cover surrounding the body sensor.
  • the user then taps an icon on the touchpanel display 55 , causing the barcode scanner 57 to scan the barcode.
  • the printed barcode includes information on the body sensor's Bluetooth transceiver that allows it to pair with the monitor's Bluetooth transceiver.
  • the scanning process decodes the barcode and translates its information to a microprocessor within the monitor 50 . Once the information is received, software running on the microprocessor analyzes it to complete the pairing. This methodology forces the user to bring the monitor into close proximity to the body sensor, thereby reducing the chance that vital sign information from another body sensor is erroneously received and displayed.
  • the above-described system determines the patient's blood pressure using PTT as shown schematically in FIGS. 8A and 8B , and then corrects this value for VI using the algorithm described below. Specifically, it is well know that a patient's arteries stiffen with biological age. This property can thus be used to estimate the patient's vascular stiffness. When used with a PTT-based measurement of blood pressure, which depends strongly on vascular stiffness, biological age can increase the accuracy of the blood pressure measurement.
  • the accuracy of the measurement can be further improved with VI, which serves as a proxy for a ‘true’ age of the patient's vasculature: patients with elastic arteries for their age will have a VI less than their biological age, while patients with stiff arteries for their age will have a VI greater than their biological age. Therefore, the difference between VI and the patient's biological age can be compared to a pre-determined correction factor to improve the accuracy of a PTT-based blood pressure measurement.
  • FIG. 3 shows an abstraction of a mathematical equation 100 that indicates how blood pressure is calculated from both PTT and VI.
  • VI is preferably calculated using a 6-step algorithm, described in more detail with reference to FIGS. 4A-F , that includes: 1) filtering an optical waveform with fill first, fixed-frequency PET-based filter; 2) taking the first and second derivatives of the filtered waveform; 3) filtering the second derivative with a second., fixed-frequency FFT-based filter; 4) analyzing the waveform using a peak-finding algorithm to determine a patient specific cutoff frequency; 5) filtering the second derivative with an adaptable-frequency FFT-based filter featuring the patient-specific cutoff frequency; and 6) analyzing the filtered, second derivative to find a series of ‘peaks’ and ‘troughs’, the amplitude of which are then processed with a mathematical formula, described below in Equation I, to calculate VI.
  • a 6-step algorithm described in more detail with reference to FIGS. 4A-F , that includes: 1) filtering an optical waveform with
  • the optical waveform is first measured and digitized using the analog-to-digital converter within the body sensor.
  • the resultant waveform is then processed using a first, PET-based digital filter.
  • FIG. 4A shows a graph 110 of a fixed-frequency filter used to remove extraneous noise from the optical waveform, e.g., noise from external power supplies, fluorescent lights, and patient motion.
  • the cutoff frequencies F low and P high are chosen such that the external noise sources are removed, but the fundamental frequencies comprising the optical waveform are unaltered.
  • FFT-based digital filtering algorithms are well known in signal processing, and are described, for example, in: Numerical Recipes in C. 1988, Cambridge University Press, the contents of which are incorporated by reference. :In one embodiment, the FFT-based filtering algorithm is a digital bandpass filter, implemented as a Finite Impulse Response Windowed-Sine Filter (FIR-WS filter).
  • the optical waveform is processed to determine its first and second mathematical derivatives; the latter is shown in the graph 111 of FIG. 4B .
  • the first derivative for each point X is calculated by choosing a window size of N and then taking the difference between the points X+(N/2) and X ⁇ (N/2). This difference is typically normalized to the window size N.
  • the second derivative is calculated in the same way, using the first derivative as input.
  • the resulting waveform includes a series of peaks and troughs, described in detail below, that are sensitive to acceleration of a volumetric absorbance change in the artery measured by the optical sensor; the amplitudes of these features are strongly influenced by the artery's vascular properties (e.g., its stiffness).
  • the first FFT-based filtering process may introduce to the optical waveform a small amount of oscillating noise at the frequency F high .
  • This noise can be amplified after taking a second derivative of the waveform, shown in FIG. 4B , and may contribute errors to the VI calculation.
  • the second derivative is processed with a second digital bandpass filter, shown schematically in the graph 112 of FIG. 4C .
  • F low for the second filter is unchanged from that shown in FIG. 4A
  • F min is chosen to be slightly less than F high .
  • the resulting second derivative lacks any oscillating noise caused by the F high cutoff filter, and typically contains first and second peaks, similar to the peaks ‘a’ and ‘e’ shown in the waveform 113 of FIG. 4D .
  • the locations of these peaks are saved in memory, and used as described below to determine various peaks and troughs.
  • the frequency difference separating peaks ‘a’ and ‘e’ yields new cutoff frequency, F adapt , which varies with each patient and is sensitive to their cardiac and vascular properties.
  • F adapt is greater than F min , but less than F high ; it is determined on a patient-specific basis to optimize removal of the oscillating noise in the second derivative, while minimizing removal of features of interest in the waveform.
  • FIG. 4F shows a graph 115 of the second derivative waveform following the adaptive filtering process.
  • the waveform has a high signal-to-noise ratio and features a series of peaks and troughs, labeled ‘a’, ‘b’, ‘c’, ‘d’, and ‘e’, which are used to calculate VI. In general, these peaks and troughs will be more pronounced, and the VI will be lower, in arteries that have more elasticity.
  • the first peak (‘a’) and the first trough (‘b’) are detected using a peak-detecting search window centered on the first peak, as shown in FIG. 4D and described above, used to determine the adaptive filter frequency F adapt .
  • the peak-detecting search window is an algorithm that determines the local maximum value of the various peaks.
  • the final peak (‘e’) is detected using a peak detecting search window centered on the last peak detected during this step.
  • the second peak (‘c’) and second trough (‘d’) are detected by performing a peak-detecting search window in the interval between the previously detected ‘b’ trough and the ‘e’ peak,
  • the amplitude of peaks and troughs ‘a’ through ‘e’ can be related to VI using equation 1, below.
  • a 1 and A 2 are predetermined constants.
  • a 1 is typically 1.515
  • a 2 is typically 0.023, as described in the following reference, the contents of which are incorporated herein by reference: Assessment of Vasoactive Agents and Vascular Aging by the Second Derivative of Photoplethysmogram Waveform , Takazawa et al., Hypertension 32:365-370, 1998.
  • VI can be used along with the patient's biological age and a predetermined correction factor to improve the accuracy of the PTT-based blood pressure calculation.
  • FIG. 5 illustrates the impact of this correction. It shows a graph 120 of a difference between VI and biological age as a function of the difference between. systolic blood pressure measured by a medical professional using a stethoscope with a cuff and aneroid sphygmomanometer (‘Cuff SYS’ in the figure) and using an uncorrected PTT measurement (‘PTT SYS’ in the figure). Data for the graph were determined by measuring 200 patients with both a device similar to that shown in FIGS. 1 and 2 , and an aneroid sphygmomanometer.
  • SYS BP (corrected) PTT -Based SYS BP +( VI ⁇ Bio Age)* M VI +B VI 2
  • Diastolic and mean blood pressures are determined in a similar manner, i.e., by first determining a relationship with PTT, and then correcting for any errors using VI, biological age, and a correction based on a pre-determined set of parameters determined from a large-patient study.
  • FIGS. 6A and 6B show graphs 125 , 126 taken from the above-described 200-patient study, wherein systolic blood pressure, measured from PTT, is plotted against blood pressure simultaneously measured using a cuff-based aneroid sphygmomanometer. Uncorrected PTT-based blood pressure values are used in the first graph 125 ( FIG. 6A ), while corrected PTT-based blood pressure values are used in the second graph 126 (FIG. 6 B). A relatively high correlation between the two blood pressure values in this type of study indicates that PTT can determine blood pressure with improved accuracy. As shown in FIG.
  • PTT-based diastolic blood pressure shows a standard deviation of 10.0 mmHg when compared to corresponding values measured with a cuff.
  • FIG. 7 shows a flowchart indicating an algorithm 159 , based on the above-described study, which can be implemented with the device shown in FIGS. 1 and 2 during a blood pressure measurement.
  • a caregiver or in another implementation, the patient attaches the body sensor, armband and optical and electrical sensors to the patient. Once attached, the sensors simultaneously measure optical, electrical, and pressure waveforms (step 160 ), as described above. These analog signals pass through into the body sensor, where they are amplified (to increase signal strength) and filtered (to remove unwanted noise and correct for low-frequency modulation) with separate circuits, and finally digitized with an analog-to-digital converter (step 161 ).
  • the optical, electrical, and pressure waveforms are processed to determine a patient-specific calibration (step 169 ), and the pressure waveform is processed to determine blood pressure values (step 166 ).
  • the digitized optical and electrical signals pass through FFT-based digital filters to remove unwanted noise (step 162 ).
  • the resulting optical waveforms are processed by analyzing their second derivative as shown in FIGS. 4B , 4 D, and 4 F, and further filtered, as shown in FIGS. 4C and 4E , to determine peaks and troughs ‘a’ through ‘e’.
  • These parameters are then processed according to Equation 1 to determine VI (step 163 ).
  • PTT is measured from the optical and electrical waveforms as shown in FIG.
  • step 164 the algorithm corrects systolic blood pressure using VI, biological age, and a set of predetermined coefficients according to Equation 2 (step 167 ). This correction accounts for patient-to-patient variation in arterial properties.
  • Mean arterial pressure and diastolic pressure are determined in a similar method, or directly from systolic blood pressure using a predetermined mathematical relationship, e.g., a linear relationship characterized by a slope and y-intercept. The slope and y-intercept of this relationship are typically determined prior to the measurement using a large (typically n>100) clinical study.
  • the optical and electrical waveforms can be further processed to determine other properties, such as heart rate, respiratory rate, and pulse oximetry (step 168 ).
  • Pulse or heart rate for example, is determined using techniques known in the art, e.g., determining the time spacing between pulses in the optical waveform, or QRS complexes in the electrical waveform, respectively.
  • Respiratory rate modulates the time-dependent properties of the envelope of the optical and/or electrical waveforms, and thus can he determined, for example, by taking a spectral transform (e.g. a wavelet or Fourier transform) of these waveforms and then analyzing for low-frequency signals.
  • the frequency of the envelope corresponds to the respiratory rate.
  • respiratory rate can be calculated using an acoustic sensor, placed on the patient's chest, that measures breathing sounds.
  • acoustic sensor placed on the patient's chest
  • Pulse oximetry can be determined from the optical waveform using well-known algorithms, such as those described in U.S. Pat. No. 4,653,498 to New, Jr. et al., the contents of which are incorporated herein by reference. Pulse oximetry requires time-dependent signals generated from two or more, separate and modulated light sources (in the red spectral range and in the infrared).
  • FIGS. 8A and 8B show schematic drawings of the composite technique's pressure-free ( FIG. 8A ) and pressure-dependent ( FIG. 8B ) measurements. Working in concert, these measurements accurately and continuously determine the patient's blood pressure for an extended time without requiring an external calibration device, e.g., a conventional blood pressure cuff.
  • the patient wears a body sensor attached to a disposable armband and optical and electrical sensors. These sensors measure signals for both the pressure dependent and pressure-free measurements.
  • a microprocessor in the body sensor processes the optical and electrical waveforms to determine PTT, which is used in both measurements of the composite technique to determine blood pressure, as is described in more detail below.
  • the armband includes an air bladder which, when pressurized with a mechanical pump, applies a pressure 207 to an underlying artery 202 , 202 ′.
  • An electrical system featuring at least 3 electrodes coupled to an amplifier/filter circuit within the body sensor measures an electrical waveform 204 , 204 ′ from the patient. Three electrodes (two detecting positive and negative signals, and one serving as a ground) are typically required to detect the necessary signals to generate an electrical waveform with an adequate signal-to-noise ratio.
  • an optical system featuring a reflective optical sensor measures an optical waveform 205 , 205 ′ featuring a series of ‘pulses’, each characterized by an amplitude of AMP 1 , AMP 2 , from the patient's artery.
  • Typical measurement sites are proximal to the brachial or radial arteries, or the smaller arteries near the base of the patient's thumb (e.g. on the palm side of the hand).
  • a microprocessor and analog-to-digital converter within the body sensor detects and analyzes the electrical 204 , 204 ′ and optical 205 , 205 ′ waveforms to determine both (from the pressure-free measurement) and PTT 2 (from the pressure dependent measurement).
  • the microprocessor determines both PTT 1 and PTT 2 by calculating the time difference between the peak of the QRS complex in the electrical waveform 204 , 204 ′ and the foot (i.e. onset) of the optical waveform 205 , 205 ′.
  • an applied pressure (indicated by arrow 207 ) during the pressure-dependent measurement affects blood flow (indicated by arrows 203 , 203 ′) in the underlying artery 202 , 202 ′.
  • the applied pressure has no affect on either PTT 2 or AMP 2 when it is less than a diastolic pressure within the artery 202 , 202 ′.
  • the applied pressure 207 reaches the diastolic pressure it begins to compress the artery, thus reducing blood flow and the effective internal pressure. This causes PTT 2 to systematically increase relative to PTT 1 , and AMP 2 to systematically decrease relative to AMP 1 .
  • PTT 2 increases and AMP 2 decreases (typically in a linear maimer) as the applied pressure 207 approaches the systolic blood pressure within the artery 202 , 202 ′.
  • AMP 2 is completely eliminated and PTT 2 consequently becomes immeasurable.
  • FIG. 9 illustrates the above-mentioned measurement in more detail.
  • the patient's heart 248 generates electrical impulses that pass through the body near the speed of light. These impulses accompany each heart heat, which then generates a pressure wave that propagates through the patient's vasculature at a significantly slower speed immediately after the heartbeat, the pressure wave leaves the heart 248 and aorta 249 , passes through the subclavian artery 250 , to the brachial artery 244 , and from there through the radial and ulnar arteries 245 to smaller arteries in the patient's fingers.
  • Three disposable electrodes located on the patient's chest measure unique electrical signals which pass to an amplifier/filter circuit within the body sensor.
  • these electrodes attach to the patient's chest in a 1-vector ‘Einthoven's triangle’ configuration to measure unique electrical signals.
  • the signals are processed using the amplifier/filter circuit to deter an analog electrical signal, which is digitized with an analog-to-digital converter to form the electrical waveform and then stored in memory.
  • the optical sensor typically includes an optical module featuring an integrated photodetector, amplifier, and pair of light sources operating near 570 nm+/ ⁇ 10 nm. This wavelength is selected because it is particularly sensitive to volumetric absorbance changes in an underlying artery for a wide variety of skin types when deployed in a reflection-mode geometry.
  • the optical sensor detects reflected radiation, which is further processed with a second amplifier/filter circuit within the body sensor. This results in the optical waveform, which, as described above, includes a series of pulses, each corresponding to an individual heartbeat.
  • the same optical and electrical sensors are used during the pressure-dependent and pressure-free measurements to measure sipals from the patient 210 .
  • Optical 213 a , 213 b and electrical 212 a , 212 b waveforms from these measurements are shown in the graphs 211 a , 211 b in the figure. In the top graph showing the pressure-dependent measurement pressure gradually decreases with time.
  • Each pulse in the optical waveforms 213 a , 213 b from both measurements corresponds to an individual heartbeat, and represents a volumetric absorbance change in an underlying artery caused by the propagating pressure pulse.
  • the electrical waveforms 212 a , 212 b from each measurement feature a series of sharp, ‘QRS’ complexes corresponding to each heartbeat.
  • QRS sharp, ‘QRS’ complexes corresponding to each heartbeat.
  • pressure has a strong impact on amplitudes of pulses in the optical waveform 213 a during the pressure dependent measurement, but has no impact on the amplitudes of QRS complexes in the corresponding electrical waveform 212 a .
  • FIG. 10 shows, in more detail, graphs of the time-dependent pressure 221 , optical 222 , and electrical 223 waveforms measured during the pressure-dependent measurement.
  • FIGS. 11A and 11B show, respectively, how PTT and the optical pulse amplitude determined from the optical 222 and electrical 223 waveforms vary with applied pressure for a typical patient. Pulses in the optical waveform 222 have no amplitude when the applied pressure is greater than systolic pressure (indicated by the dashed line 219 ) in the underlying artery. The pulses begin to appear when the applied pressure is equivalent to systolic blood pressure. Their amplitude increases, and their PTT decreases, as applied pressure decreases. These trends continue until diastolic pressure is reached. At this point, the amplitude of the pulses and the associated PTT values are relatively constant. QRS complexes in electrical waveform 223 are unaffected by the applied pressure.
  • the body sensor collects data like that shown in FIGS. 11A and 11B , for an individual patient.
  • a conventional peak-detecting algorithm running on the microprocessor in the body sensor detects the onset of the optical pulse amplitude, shown in FIG. 11B , to make a direct measurement of systolic blood pressure.
  • a ‘fitting’ algorithm can model the systematic decrease in pulse amplitude with applied pressure with a mathematical function (e.g. a linear function) to estimate systolic blood pressure.
  • the microprocessor analyzes the variation between applied pressure and PTT, shown graphically in FIG. 11A , to estimate the relationship between blood pressure and PTT.
  • Equation 3 this relationship is best described with a mathematical model that first estimates how the patient's ‘effective’ mean arterial blood pressure (MAP*(P)) varies with applied pressure (P applied ). The model assumes that pressure applied by the armband occludes the patient's brachial artery, and thus temporarily decreases blood flow. This, in turn, increases blood pressure directly underneath the armband, and reduces blood pressure in the downstream radial, ulnar, and finger arteries.
  • the net effect is a temporary, pressure-dependent reduction in the patient's mean arterial blood pressure (MAP), indicated in equation 1 as AMAP(P), during the pressure-dependent measurement.
  • MAP mean arterial blood pressure
  • AMAP(P) mean arterial blood pressure
  • F an empirically determined factor accounts for the ratio between the region of increased blood pressure (underneath the armband; approximately 10 cm) and the larger region of decreased blood pressure (the length of the arm downstream from the armband; approximately 50 cm). F is typically between 0.6 and 0.9, and is preprogrammed into the algorithm prior to measurement.)
  • Equation 3 paired values of PTT and MAP*(P) are determined for each heartbeat as the applied pressure increases from the diastolic pressure to mean arterial pressure.
  • This approach yields multiple data points during a single pressure-dependent measurement that can then be fit with a mathematical function (e.g. a linear function) relating PTT to mean arterial pressure.
  • a mathematical function e.g. a linear function
  • these parameters are inversely related, i.e. PTT gets shorter and blood pressure increases.
  • an inverse linear relationship determined during the pressure-dependent measurement is then used during subsequent pressure-free measurements to convert the measured PTT into blood pressure values.
  • Equation 3 the values for diastolic blood pressure (DIA) and mean arterial pressure (MAP) are determined with an oscillometric blood pressure measurement during inflation.
  • Systolic blood pressure (SYS) can either be determined indirectly during the oscillometric blood pressure measurement, or directly using the above-described method involving the pulse amplitude in the optical waveform. From these values, the SYS/MAP and DIA/MAP ratios can be determined. These ratios are typically constant for a given patient over a range of blood pressures. They can be used during the pressure-free measurements, along with the PTT-dependent mean arterial pressure, to determine systolic and diastolic blood pressures.
  • the oscillometric blood pressure measurement analyzes the pressure waveform ( 221 in FIG. 10 ) that is measured by the armband, Performing this measurement during inflation expedites the measurement and increases patient comfort.
  • most conventional cuff-based systems using the oscillometric technique analyze their pressure waveform during deflation, resulting in a measurement that is roughly 4 times longer than the composite technique's pressure-dependent measurement. Inflation-based measurements are possible because of the composite technique's relatively slow inflation speed (typically 5-10 mmHg/second) and the high sensitivity of the pressure sensor used within the body sensor.
  • measurements made during inflation can be immediately terminated once systolic blood pressure is calculated.
  • conventional cuff-based measurements made during deflation typically apply a pressure that far exceeds the patient's systolic blood pressure; pressure within the cuff then slowly bleeds down below the diastolic pressure to complete the measurement.
  • optical waveform such as the width, rise time, fall time, dichrotic notch, general shape, or any other feature that indicates arterial properties, can be used to estimate the stiffness of the patient's arteries and used along with PTT to improve the accuracy of the blood pressure measurement.
  • software configurations other than those described above can be run on the bedside device to give it a PDA-like functionality.
  • These include, for example, Micro COS®, Linux®, Microsoft Windows®, embOS, VxWorks, SymhianOS, QNX, OSE, BSD and its variants, FreeDOS, FreeRTOX, LynxOS, or eCOS and other embedded operating systems.
  • the device can also run a software configuration that allows it to receive and send voice calls, text messages, or video streams received through the Internet or from the nation-wide wireless network it connects to.
  • a bar-code scanner can also be incorporated into the device to capture patient or medical professional identification information, or other such labeling.
  • the device can connect to an Internet-accessible website to download content, e.g., calibrations, software updates, text messages, and information describing medications, from an associated website.
  • content e.g., calibrations, software updates, text messages, and information describing medications
  • the device can connect to the website using both wired (e.g., USB port) or wireless (e.g., short or long-range wireless transceivers) means.
  • ‘alert’ values corresponding to vital signs and the pager or cell phone number of a caregiver can be programmed into the device using its graphical user interface.
  • a patient's vital signs meet an alert criteria
  • software on the device can send a wireless ‘page’ to the caregiver, thereby alerting them to the patient's condition.
  • a confirmation scheme can be implemented that alerts other individuals or systems until acknowledgment of the alert is received.

Abstract

A method and apparatus for measuring a patient's blood pressure featuring the following steps: 1) measuring a time-dependent optical waveform with an optical sensor; 2) measuring a time-dependent electrical signal with an electrical sensor; 3) estimating the patient's arterial properties using the optical waveform; 4) determining a pulse transit time (PTT) from the time-dependent electrical signal and the time-dependent optical waveform; and 5) calculating a blood pressure value using a mathematical model that includes the PTT and the patient's arterial properties.

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • This application claims the benefit of U.S. Provisional Application No. 60/943,523, filed Jun. 12, 2007, incorporated herein by reference.
  • FIELD OF THE INVENTION
  • The present invention generally relates to medical devices for monitoring vital signs, e.g., arterial blood pressure.
  • BACKGROUND OF THE INVENTION
  • Pulse transit time (PTT), defined as the transit time for a pressure pulse launched by a heartbeat in a patient's arterial system, has been shown in a number of studies to correlate to both systolic and diastolic blood pressure. In these studies, PTT is typically measured with a conventional vital sips monitor that includes separate modules to determine both an electrocardiogram (ECG) and pulse oximetry. During a PTT measurement, multiple electrodes typically attach to a patient's chest to determine a time-dependent ECG component characterized by a sharp spike called the ‘QRS complex’. This feature indicates an initial depolarization of ventricles within the heart and, informally, marks the beginning of the heartbeat and a pressure pulse that follows. Pulse oximetry is typically measured with a bandage or clothespin-shaped sensor that attaches to a patient's finger, and includes optical systems operating in both the red and infrared spectral regions. A photodetector measures radiation emitted from the optical systems and transmitted through the patient's finger. Other body sites, e.g., the ear, forehead, and nose, can also be used in place of the finger. During a measurement, a microprocessor analyses both red and infrared radiation measured by the photodetector to determine the patient's blood oxygen saturation level and a time-dependent waveform called an optical waveform or plethysmograph. Time-dependent features of the optical waveform indicate both pulse rate and a volumetric absorbance change in an underlying artery (e.g., in the finger) caused by the propagating pressure pulse.
  • Typical PTT measurements determine the time separating a maximum point on the QRS complex (indicating the peak of ventricular depolarization) and a foot of the optical waveform (indicating the beginning the pressure pulse). PTT depends primarily on arterial compliance, the propagation distance of the pressure pulse (closely approximated by the patient's arm length), and blood pressure. To account for patient-dependent properties, such as arterial compliance, PTT-based measurements of blood pressure are typically ‘calibrated’ using a conventional blood pressure cuff. Typically during the calibration process the blood pressure cuff is applied to the patient, used to make one or more blood pressure measurements, and then removed. Going forward, the calibration blood pressure measurements are used, along with a change in PTT, to estimate the patient's blood pressure and blood pressure variability. PTT typically relates inversely to blood pressure, i.e., a decrease in PTT indicates an increase in blood pressure.
  • A number of issued U.S. Patents describe the relationship between PTT and blood pressure. For example, U.S. Pat. Nos. 5,316,008; 5,857,975; 5,865,755; and 5,649,543 each describe an apparatus that includes conventional sensors that measure an ECG and optical waveform, which are then processed to determine PTT.
  • SUMMARY OF THE INVENTION
  • Embodiments described herein provide a medical device that makes a cuffless measurement of blood pressure using PTT and a correction that accounts for the patient's arterial properties (e.g., stiffness and size). This correction, referred to herein as a ‘vascular index’ (‘VP’), improves the accuracy of a PTT-based blood pressure measurement by estimating the patient's arterial stiffness by analyzing one or more optical waveforms used in the PTT calculation. A patient's arteries typically stiffen with age, and thus biological age provides an initial estimate arterial stiffness. In certain described embodiments, VI is used along with biological age to further improve the accuracy of PTT-calculated blood pressure, as it serves as a proxy for a ‘true’ age of the patient's vasculature: patients with elastic arteries for their age will have a VI less than their biological age. While patients with stiff arteries for their age will have a VI greater than their biological age. VI, as used in this application, has the units of years.
  • As described herein, an optical waveform yields a VI after it is passed through digital filters and processed with a series of mathematical algorithms. The digital filters are implemented using Fast Fourier Transforms (‘FFT’, also referred to herein as a ‘Windowed-Sine Digital Filter’). Once calculated, the VI is used in combination with the patient's biological age to estimate their arterial properties. These properties are then used to ‘correct’ the blood pressure determination that was determined by the PTT and thus calculate blood pressure without the need for an external calibration (e.g., without input of an external blood pressure measurement., e.g. an auscultatory or oscillometric measurement).
  • Embodiments described herein are based on the realization that a. PTT-based blood pressure measurement, corrected for the patient's arterial properties using age and VI, shows a better correlation to actual blood pressure than one that is based on PTT alone. Moreover, the correlation between PTT and blood pressure is further improved by measuring PTT using ECG (referred to herein as an ‘electrical waveform’) and an optical waveform measured near the patient's brachial artery (i.e., near the patient's elbow, superior to the medial epicondyle) or radial artery (e.g., the common site for feeling a pulse near the patient's wrist). Due to the thickness of tissue in these regions, the optical waveform is best measured using a reflective optical sensor. In this configuration, the signal-to-noise ratio of the waveform can be increased by using a multi-sensor array instead of a single sensor, and by choosing an optical wavelength (λ˜570 nm) that works well in reflection-mode geometry for a variety of skin pigmentations. This wavelength may vary slightly (i.e. from 560-580 nm) without affecting the measurement.
  • The above-described method for calculating blood pressure using PTT and a correction derived from VI can be used in a ‘composite’ blood pressure measurement technique featuring both pressure-dependent and pressure-free components. Specifically, the composite technique determines blood pressure using: 1) a first, pressure-dependent step that analyzes both PTT and the amplitude of the optical waveform while pressure is applied to the patient's brachial artery; and 2) a second, pressure-free measurement of PTT and information from the pressure-dependent measurement in routine clinical use, the pressure-free approach typically makes up about 95% of the composite technique's total measurements; pressure-dependent measurements are typically used to calibrate the device and to correct any time-dependent drift in the pressure-free measurements. Drill may occur, for example, due to changes in the patient's temperature, arterial tone and compliance, or cardiac pre-injection period. Both the pressure-dependent and pressure-free measurements use the same measurement system, which features both optical and electrical sensors to measure PTT. The composite technique accurately and continuously determines the patient's blood pressure over an extended time without requiring an external calibration device, e.g., an external blood pressure cuff.
  • The composite technique is also based on the discovery that PTT, measured in the presence of an applied pressure, typically increases when the applied pressure is equal to or greater than the patient's diastolic blood pressure. As the applied pressure gradually increases to the patient's systolic pressure, PTT continues to increase, typically in a linear manner. When the applied pressure equals systolic blood pressure, the amplitude of an optical waveform measured below the region of applied pressure decreases to zero, and the PTT is no longer measurable. Thus, analyzing both PTT and the optical waveform's amplitude over a suitable range yields the patient's systolic blood pressure. Further analysis of the pressure-dependent increase in PTT yields a calibration that relates PTT and blood pressure for the particular patient. Once determined, these parameters are used with a PTT measured with the same optical and electrical sensors (but no applied pressure) to continuously measure the patient's blood pressure.
  • PTT, VI and blood pressure, along with other information such as pulse pressure, blood pressure variability, heart rate, heart rate variability, respiratory rate, pulse oximetry, pulse wave velocity, and temperature, are analyzed with a hand-held device that includes many features of a conventional personal digital assistant (PDA). The device includes, for example, a microprocessor that runs an icon-driven graphical user interface (GUI) on a color, liquid crystal display attached to a touch panel. A user selects different measurement modes, such as continuous measurements in the hospital, one-time measurements at home and in the hospital, and 24-hour ambulatory measurements, by tapping a stylus on an appropriate icon within the GUI. The device also includes several other hardware features commonly found in PDAs, such as short-range (e.g., Bluetooth® and WiFi® and long-range (e.g., CDMA, GSM, IDEN) modems, global positioning system, digital camera, and barcode scanner.
  • In one aspect, for example, the described embodiment provides a method for measuring a patient's blood pressure that includes: 1) measuring a time-dependent optical waveform with an optical sensor; 2) measuring a time-dependent electrical waveform with an electrical sensor; 3) determining a VI from the time-dependent optical waveform; 4) determining a PTT from the time-dependent electrical signal from the heart and the time-dependent optical waveform; 5) calculating a blood pressure value using a mathematical model that includes PTT and a predetermined relationship between PTT and blood pressure; and 6) correcting the blood pressure with the VI and the patient's biological age.
  • In embodiments, the method includes determining the VI by analyzing the properties (e.g., taken from the second derivative) of the first optical waveform. To measure the optical waveform, for example, the optical sensor typically operates in a transmission or reflection-mode geometry near the patient's brachial, radial or ulnar arteries. Typically 3 electrodes, disposed on the patient in a conventional ‘Einthoven's triangle’ configuration, detect electrical signals which, once processed, determine the electrical waveform.
  • The embodiments of the invention have one or more of the following advantages. In general, the device described herein uses both PTT and VI to make a continuous, cuffless measurement of blood pressure. This allows, for example, patients to be better monitored in hospitals and medical clinics. Moreover, the device combines all the data-analysis features and form factor of a conventional PDA with the monitoring capabilities of a conventional vital sign monitor. This results in an easy-to-use, flexible device that performs one-time, continuous, and ambulatory measurements both in and outside of a hospital. Moreover, the optical and electrical sensors can be connected to a comfortable, lightweight body sensor that wirelessly communicates with monitor. This eliminates the wires that normally tether a patient to a conventional vital sign monitor, thereby increasing patient comfort and enabling mobility.
  • The details of one or more embodiments of the invention are set forth in the accompanying drawings and the description below. Other features, objects, and advantages of the invention will he apparent from the description and drawings, and from the claims.
  • BRIEF DESCRIPTION
  • FIG. 1 is a top view of a circuit board used in the body sensor.
  • FIG. 2 is a three-dimensional plan view of the monitor.
  • FIG. 3 shows an abstraction of a mathematical equation describing how blood pressure can be calculated from PTT and VI.
  • FIGS. 4A, 4C, and 4E are graphs of, respectively, a first fixed-frequency handpass filter, a second fixed-frequency bandpass filter, and an adaptive handpass filter used during waveform analysis.
  • FIG. 4B is a graph of a second derivative of the optical waveform after filtering with the first fixed-frequency bandpass filter of FIG. 4A,
  • FIG. 4D is a graph of a second derivative of the optical waveform after filtering with the second fixed-frequency bandpass filter of FIG. 4C.
  • FIG. 4F is a graph of a second derivative of the optical waveform after filtering with the second fixed-frequency and adaptive-frequency bandpass filters of, respectively, FIGS. 4C and 4E.
  • FIG. 5 is a graph of an error in systolic blood pressure vs. the difference between VI and age for a 200-patient study.
  • FIGS. 6A and 6B are graphs showing the correlation of systolic blood pressure measured with a cuff vs. systolic blood pressure measured according to the approach described herein determined, respectively, before and after the VI correction.
  • FIG. 7 is a flow chart showing an algorithm used to measure blood pressure by analyzing PTT and VI.
  • FIGS. 8A and 8B show, respectively, schematic drawings of pressure-free and pressure-dependent measurements used in the composite technique.
  • FIG. 9 shows a schematic drawing of a patient and optical and electrical waveforms measured during the pressure-dependent and pressure-free measurements of FIGS. 8A and 8B.
  • FIG. 10 shows graphs of time-dependent pressure, optical, and electrical waveforms measured with the body sensor and the optical, electrical, and pressure sensors.
  • FIGS. 11A and 11B show graphs of, respectively, PTT and the amplitude of the optical waveform as a function of pressure.
  • DETAILED DESCRIPTION
  • FIGS. 1 and 2 show a system featuring a body sensor and monitor that performs a PTT-based blood pressure measurement, corrected for VI, on a patient. The blood pressure measurement features pressure-dependent and pressure-free measurements. The system measures: i) an optical waveform from the patient with an optical sensor; ii) an electrical waveform using an electrical sensor featuring multiple ECG electrodes; and iii) a pressure waveform using armband featuring an inflatable bladder. A first algorithm operating on the body sensor, described in detail below, analyzes the optical waveform to estimate VI. A second algorithm calculates PTT from the electrical and optical waveforms, and uses this value to calculate blood pressure. VI and biological age are then compared to a predetermined correction factor aid used adjust the PTT-determined blood pressure value.
  • FIG. 1 shows a top view of the body sensor 1 used to conduct the above-described measurements. The body sensor 1 features a single circuit board 12 including connectors 5, 15 that connect through separate cables 19, 21 to, respectively, the electrical sensor (electrodes worn on the patient's chest) and optical sensor (worn on the patient's wrist). During both pressure-dependent and pressure-free measurements, these sensors measure electrical and optical signals that pass through the connectors 5, 15 to discrete circuit components 11 on the bottom side of the circuit board 12. The discrete components 11 include: i) analog circuitry for amplifying and filtering the time-dependent optical and electrical waveforms; ii) an analog-to-digital converter for converting the time-dependent analog signals into digital waveforms; and iii) a microprocessor for processing the digital waveforms to determine blood pressure according to the composite technique, along with other vital signs.
  • To measure the pressure waveform during a pressure-dependent measurement, the circuit board 12 additionally includes a small mechanical pump 4 for inflating the bladder within the armband, and first and second solenoid values 3 a, 3 b for controlling the bladder's inflation and deflation rates. The pump 4 and solenoid valves 3 a, 3 b connect through a manifold 7 to a connector 10 that attaches through a tube (not shown in the figure) to the bladder in the armband, and additionally to a digital pressure sensor 16 that senses the pressure in the bladder. The first solenoid valve 3 a couples through the manifold 7 to a small ‘bleeder’ valve 17 featuring a small hole that slowly releases pressure. The second solenoid valve 3 b is coupled through the manifold 7 and rapidly releases pressure. Typically both solenoid valves 3 a, 3 b are closed as the pump 4 inflates the bladder. For measurements conducted during inflation, pulsations caused by the patient's heartbeats couple into the bladder as it inflates, and are mapped onto the pressure waveform. The digital pressure sensor 16 generates an analog pressure waveform, which is then digitized with the analog-to-digital converter described above. The microprocessor processes the digitized pressure, optical, and electrical waveforms to deter mine systolic, mean arterial, and diastolic blood pressures. Once these measurements are complete, the microprocessor immediately opens the second solenoid valve 3 b, causing the bladder to rapidly deflate.
  • Alternatively, for measurements done on deflation, the pump 4 inflates the bladder to a pre-programmed pressure above the patient's systolic pressure. Once this pressure is reached, the microprocessor opens the first solenoid valve 3 a, which couples to the ‘bleeder’ valve 17 to slowly release the pressure. During this deflation period, pulsations caused by the patient's heartbeat are coupled into the bladder and are mapped onto the pressure waveform, which is then measured by the digital pressure sensor 16. Once the microprocessor determines systolic, mean arterial, and diastolic blood pressure, it opens the second solenoid valve 3 b to rapidly evacuate the pressure.
  • Four AA batteries 2 mount directly on the circuit board 12 to power all the above-mentioned circuit components. The board 12 additionally includes a plug 6 which accepts power from a wall-mounted AC adaptor. The AC adaptor is used, for example, when measurements are made over an extended period of time A rugged plastic housing (not shown in the figure) covers the circuit board 12 and all its components. A Bluetooth transmitter 23 is mounted directly on the circuit board 12 and, following a measurement, wirelessly transmits information to an external monitor.
  • The optical modules within the optical sensor typically include an LED operating near 570 nm, a photodetector, and an amplifier. This wavelength is selected because, when deployed in a reflection-mode geometry, it is particularly sensitive to volumetric absorbance changes in an underlying artery for a wide variety of skin pigmentations. A preferred sensor is described in the following co-pending patent application, the entire contents of which are incorporated herein by reference: SYSTEM FOR MEASURING VITAL SIGNS USING AN OPTICAL MODULE FEATURING A GREEN LIGHT SOURCE (U.S. Ser. No. 11/307,375; filed Feb. 3, 2006). Typically, multiple optical modules are used in the sensor to increase the probability that an underlying (or proximal) artery is measured, thus increasing the signal-to-noise ratio of the measurement. Operating in concert, the multiple sensors collectively measure an optical waveform that includes photocurrent generated by each optical module. The resultant signal forms the optical waveform, and effectively represents an ‘average’ signal measured from vasculature (e.g., arteries, arterioles and capillaries) underneath the sensor. The optical sensor can additionally include LEDs operating near 650 nm and 950 nm in order to make a pulse oximetry measurement.
  • FIG. 2 shows a three-dimensional plan view of the monitor 50 that receives the Bluetooth-transmitted information. The front face of the monitor 50 includes a touchpanel display 55 that renders an icon-driven graphical user interface, and a circular on/off button 59. During an actual measurement, the touchpanel display 55 renders vital sip information from the body sensor. Such a monitor has been described previously in BLOOD PRESSURE MONITOR (U.S. Ser. No. 11/530,076; filed Sep. 8, 2006) and MONITOR FOR MEASURING VITAL SIGNS AND RENDER [NO VIDEO IMAGES (U.S. Ser. No. 11/682,177; filed Mar. 5, 2007), the contents of which are incorporated herein by reference. The monitor 50 includes an internal Bluetooth transmitter (not shown in the figure) that can include an antenna 60 to increase the strength of the received signal. To pair with a body sensor, such as that shown in FIG. 1, the monitor 50 includes a barcode scanner 57 on its top surface. During operation, a user holds the monitor 50 in one hand, and points the barcode scanner 57 at a printed barcode adhered to the plastic cover surrounding the body sensor. The user then taps an icon on the touchpanel display 55, causing the barcode scanner 57 to scan the barcode. The printed barcode includes information on the body sensor's Bluetooth transceiver that allows it to pair with the monitor's Bluetooth transceiver. The scanning process decodes the barcode and translates its information to a microprocessor within the monitor 50. Once the information is received, software running on the microprocessor analyzes it to complete the pairing. This methodology forces the user to bring the monitor into close proximity to the body sensor, thereby reducing the chance that vital sign information from another body sensor is erroneously received and displayed.
  • The above-described system determines the patient's blood pressure using PTT as shown schematically in FIGS. 8A and 8B, and then corrects this value for VI using the algorithm described below. Specifically, it is well know that a patient's arteries stiffen with biological age. This property can thus be used to estimate the patient's vascular stiffness. When used with a PTT-based measurement of blood pressure, which depends strongly on vascular stiffness, biological age can increase the accuracy of the blood pressure measurement. The accuracy of the measurement can be further improved with VI, which serves as a proxy for a ‘true’ age of the patient's vasculature: patients with elastic arteries for their age will have a VI less than their biological age, while patients with stiff arteries for their age will have a VI greater than their biological age. Therefore, the difference between VI and the patient's biological age can be compared to a pre-determined correction factor to improve the accuracy of a PTT-based blood pressure measurement.
  • FIG. 3, for example, shows an abstraction of a mathematical equation 100 that indicates how blood pressure is calculated from both PTT and VI. As indicated in the figure, VI is preferably calculated using a 6-step algorithm, described in more detail with reference to FIGS. 4A-F, that includes: 1) filtering an optical waveform with fill first, fixed-frequency PET-based filter; 2) taking the first and second derivatives of the filtered waveform; 3) filtering the second derivative with a second., fixed-frequency FFT-based filter; 4) analyzing the waveform using a peak-finding algorithm to determine a patient specific cutoff frequency; 5) filtering the second derivative with an adaptable-frequency FFT-based filter featuring the patient-specific cutoff frequency; and 6) analyzing the filtered, second derivative to find a series of ‘peaks’ and ‘troughs’, the amplitude of which are then processed with a mathematical formula, described below in Equation I, to calculate VI.
  • Referring to FIGS. 4A-F, for the algorithm the optical waveform is first measured and digitized using the analog-to-digital converter within the body sensor. The resultant waveform is then processed using a first, PET-based digital filter. FIG. 4A, for example, shows a graph 110 of a fixed-frequency filter used to remove extraneous noise from the optical waveform, e.g., noise from external power supplies, fluorescent lights, and patient motion. Typically, the optical waveform is filtered using a filter that passes frequencies between Flow=0.1 Hz and Fhigh=25 Hz, and rejects any frequencies outside of this range. In general, the cutoff frequencies Flow and Phigh are chosen such that the external noise sources are removed, but the fundamental frequencies comprising the optical waveform are unaltered. FFT-based digital filtering algorithms are well known in signal processing, and are described, for example, in: Numerical Recipes in C. 1988, Cambridge University Press, the contents of which are incorporated by reference. :In one embodiment, the FFT-based filtering algorithm is a digital bandpass filter, implemented as a Finite Impulse Response Windowed-Sine Filter (FIR-WS filter).
  • Once filtered, the optical waveform is processed to determine its first and second mathematical derivatives; the latter is shown in the graph 111 of FIG. 4B. The first derivative for each point X is calculated by choosing a window size of N and then taking the difference between the points X+(N/2) and X−(N/2). This difference is typically normalized to the window size N. The second derivative is calculated in the same way, using the first derivative as input. The resulting waveform includes a series of peaks and troughs, described in detail below, that are sensitive to acceleration of a volumetric absorbance change in the artery measured by the optical sensor; the amplitudes of these features are strongly influenced by the artery's vascular properties (e.g., its stiffness).
  • The first FFT-based filtering process, shown schematically in FIG. 4A, may introduce to the optical waveform a small amount of oscillating noise at the frequency Fhigh. This noise can be amplified after taking a second derivative of the waveform, shown in FIG. 4B, and may contribute errors to the VI calculation. To mitigate this, the second derivative is processed with a second digital bandpass filter, shown schematically in the graph 112 of FIG. 4C. Flow for the second filter is unchanged from that shown in FIG. 4A, while Fmin is chosen to be slightly less than Fhigh. After filtering, the resulting second derivative lacks any oscillating noise caused by the Fhigh cutoff filter, and typically contains first and second peaks, similar to the peaks ‘a’ and ‘e’ shown in the waveform 113 of FIG. 4D. The locations of these peaks are saved in memory, and used as described below to determine various peaks and troughs. Additionally, as shown by the waveform 114 in FIG. 4E, the frequency difference separating peaks ‘a’ and ‘e’ yields new cutoff frequency, Fadapt, which varies with each patient and is sensitive to their cardiac and vascular properties. Fadapt is greater than Fmin, but less than Fhigh; it is determined on a patient-specific basis to optimize removal of the oscillating noise in the second derivative, while minimizing removal of features of interest in the waveform.
  • Once Fadapt is determined, the second derivative shown in FIG. 4B is filtered a second time using Flow as a low-frequency cutoff and Fadapt as a patient-dependent, high-frequency cutoff FIG. 4F shows a graph 115 of the second derivative waveform following the adaptive filtering process. The waveform has a high signal-to-noise ratio and features a series of peaks and troughs, labeled ‘a’, ‘b’, ‘c’, ‘d’, and ‘e’, which are used to calculate VI. In general, these peaks and troughs will be more pronounced, and the VI will be lower, in arteries that have more elasticity. The first peak (‘a’) and the first trough (‘b’) are detected using a peak-detecting search window centered on the first peak, as shown in FIG. 4D and described above, used to determine the adaptive filter frequency Fadapt. The peak-detecting search window is an algorithm that determines the local maximum value of the various peaks. The final peak (‘e’) is detected using a peak detecting search window centered on the last peak detected during this step. Finally, the second peak (‘c’) and second trough (‘d’) are detected by performing a peak-detecting search window in the interval between the previously detected ‘b’ trough and the ‘e’ peak,
  • Once determined, the amplitude of peaks and troughs ‘a’ through ‘e’ can be related to VI using equation 1, below.

  • VI(A 1[(b-c-d-e])/A 2   1)
  • where A1 and A2 are predetermined constants. A1 is typically 1.515, and A2 is typically 0.023, as described in the following reference, the contents of which are incorporated herein by reference: Assessment of Vasoactive Agents and Vascular Aging by the Second Derivative of Photoplethysmogram Waveform, Takazawa et al., Hypertension 32:365-370, 1998.
  • Once determined, VI can be used along with the patient's biological age and a predetermined correction factor to improve the accuracy of the PTT-based blood pressure calculation. FIG. 5 illustrates the impact of this correction. It shows a graph 120 of a difference between VI and biological age as a function of the difference between. systolic blood pressure measured by a medical professional using a stethoscope with a cuff and aneroid sphygmomanometer (‘Cuff SYS’ in the figure) and using an uncorrected PTT measurement (‘PTT SYS’ in the figure). Data for the graph were determined by measuring 200 patients with both a device similar to that shown in FIGS. 1 and 2, and an aneroid sphygmomanometer. The patient's biological age was determined with a survey prior to the measurement. As is clear from the figure, comparison of these parameters yields a systematic, linear relationship, characterized by a correlation coefficient of r 0.69 and shown by the grey line used to it the data. The slope (MVI) and y-intercept (BVI) extracted from the fit (1.1 mmHg/years and 2.16 mmHg, respectively) are fixed, predetermined parameters used for the correction. These values, which are determined from a statistically significant number of patients, can be used as the predetermined corrector factor with the above--described algorithm. Specifically, systolic blood pressure can be calculated according to Equation 2, below:

  • SYS BP (corrected)=PTT-Based SYS BP+(VI−Bio Age)*M VI +B VI   2
  • Diastolic and mean blood pressures are determined in a similar manner, i.e., by first determining a relationship with PTT, and then correcting for any errors using VI, biological age, and a correction based on a pre-determined set of parameters determined from a large-patient study.
  • Referring again to FIG. 5, it is apparent that for the above-described 200-patient study, errors in the PTT-based blood pressure measurement fall into two distinct categories, each represented by quadrants in the graph 120. The upper right-hand quadrant, labeled ‘I’ in the graph, consists of patients that have relatively stiff arteries for their age. For this demographic, PTT consistently underestimates the patient's blood pressure. The lower left-hand quadrant, labeled ‘III’ in the graph, consists of patients that have relatively elastic arteries for their age, and have blood pressures that PTT consistently overestimates.
  • FIGS. 6A and 6B show graphs 125, 126 taken from the above-described 200-patient study, wherein systolic blood pressure, measured from PTT, is plotted against blood pressure simultaneously measured using a cuff-based aneroid sphygmomanometer. Uncorrected PTT-based blood pressure values are used in the first graph 125 (FIG. 6A), while corrected PTT-based blood pressure values are used in the second graph 126 (FIG. 6B). A relatively high correlation between the two blood pressure values in this type of study indicates that PTT can determine blood pressure with improved accuracy. As shown in FIG. 6A, without any VI correction, PIT-based systolic blood pressure correlates with cuff-based blood pressure with r=0.65 and a standard deviation (calculated from the difference of the two measurements) of 16.2 mmHg. PTT-based diastolic blood pressure (not shown in the graph) shows a standard deviation of 10.0 mmHg when compared to corresponding values measured with a cuff. These values, as shown with graph 126 in FIG. 6B, are significantly improved when the measurement is corrected for VI. Specifically, the VI correction improved the correlation (r=0.79) and standard deviations of both systolic (SD=±13.2 mmHg) and diastolic (SD=±8.2 mmHg) blood pressure. While the study used to generate these data is somewhat limited, it indicates that the VI correction improves the accuracy of PTT-determined blood pressure. Accurately measuring such high blood pressures is particularly important, as they are often used to identify patients in need of anti-hypertension therapy. High blood pressure is a known predictor of cardiovascular disease, such as stroke, coronary artery disease, heart failure, renal failure and cardiac arrest.
  • FIG. 7 shows a flowchart indicating an algorithm 159, based on the above-described study, which can be implemented with the device shown in FIGS. 1 and 2 during a blood pressure measurement. Prior to the measurement, a caregiver (or in another implementation, the patient) attaches the body sensor, armband and optical and electrical sensors to the patient. Once attached, the sensors simultaneously measure optical, electrical, and pressure waveforms (step 160), as described above. These analog signals pass through into the body sensor, where they are amplified (to increase signal strength) and filtered (to remove unwanted noise and correct for low-frequency modulation) with separate circuits, and finally digitized with an analog-to-digital converter (step 161). The optical, electrical, and pressure waveforms are processed to determine a patient-specific calibration (step 169), and the pressure waveform is processed to determine blood pressure values (step 166).
  • As shown in FIG. 4A, the digitized optical and electrical signals pass through FFT-based digital filters to remove unwanted noise (step 162). Once filtered, the resulting optical waveforms are processed by analyzing their second derivative as shown in FIGS. 4B, 4D, and 4F, and further filtered, as shown in FIGS. 4C and 4E, to determine peaks and troughs ‘a’ through ‘e’. These parameters are then processed according to Equation 1 to determine VI (step 163). PTT is measured from the optical and electrical waveforms as shown in FIG. 8A (step 164), and then used to calculate mean arterial, systolic, and diastolic blood pressure (step 165) using the patient-specific calibration (step 169) and the initial blood pressure values determined from the pressure waveform (step 166). Once determined, the algorithm corrects systolic blood pressure using VI, biological age, and a set of predetermined coefficients according to Equation 2 (step 167). This correction accounts for patient-to-patient variation in arterial properties. Mean arterial pressure and diastolic pressure are determined in a similar method, or directly from systolic blood pressure using a predetermined mathematical relationship, e.g., a linear relationship characterized by a slope and y-intercept. The slope and y-intercept of this relationship are typically determined prior to the measurement using a large (typically n>100) clinical study.
  • Once blood pressure is determined, the optical and electrical waveforms can be further processed to determine other properties, such as heart rate, respiratory rate, and pulse oximetry (step 168). Pulse or heart rate, for example, is determined using techniques known in the art, e.g., determining the time spacing between pulses in the optical waveform, or QRS complexes in the electrical waveform, respectively. Respiratory rate modulates the time-dependent properties of the envelope of the optical and/or electrical waveforms, and thus can he determined, for example, by taking a spectral transform (e.g. a wavelet or Fourier transform) of these waveforms and then analyzing for low-frequency signals. The frequency of the envelope corresponds to the respiratory rate. Alternatively, respiratory rate can be calculated using an acoustic sensor, placed on the patient's chest, that measures breathing sounds. These two methodologies can be used in tandem and the signals used to corroborate respiratory rate. Pulse oximetry can be determined from the optical waveform using well-known algorithms, such as those described in U.S. Pat. No. 4,653,498 to New, Jr. et al., the contents of which are incorporated herein by reference. Pulse oximetry requires time-dependent signals generated from two or more, separate and modulated light sources (in the red spectral range and in the infrared).
  • The above-described method can be used in the composite technique, which features both pressure-dependent and pressure-free measurements and is described in greater detail in U.S.S.N. (TBD), entitled VITAL SIGN MONITOR FOR MEASURING BLOOD PRESSURE USING OPTICAL, ELECTRICAL, AND PRESSURE WAVEFORMS, filed Jun. 12, 2008. FIGS. 8A and 8B show schematic drawings of the composite technique's pressure-free (FIG. 8A) and pressure-dependent (FIG. 8B) measurements. Working in concert, these measurements accurately and continuously determine the patient's blood pressure for an extended time without requiring an external calibration device, e.g., a conventional blood pressure cuff. During a measurement, the patient, wears a body sensor attached to a disposable armband and optical and electrical sensors. These sensors measure signals for both the pressure dependent and pressure-free measurements. A microprocessor in the body sensor processes the optical and electrical waveforms to determine PTT, which is used in both measurements of the composite technique to determine blood pressure, as is described in more detail below.
  • The armband includes an air bladder which, when pressurized with a mechanical pump, applies a pressure 207 to an underlying artery 202, 202′. An electrical system featuring at least 3 electrodes coupled to an amplifier/filter circuit within the body sensor measures an electrical waveform 204, 204′ from the patient. Three electrodes (two detecting positive and negative signals, and one serving as a ground) are typically required to detect the necessary signals to generate an electrical waveform with an adequate signal-to-noise ratio. At the same time, an optical system featuring a reflective optical sensor measures an optical waveform 205, 205′ featuring a series of ‘pulses’, each characterized by an amplitude of AMP1, AMP2, from the patient's artery. Typical measurement sites are proximal to the brachial or radial arteries, or the smaller arteries near the base of the patient's thumb (e.g. on the palm side of the hand). A microprocessor and analog-to-digital converter within the body sensor detects and analyzes the electrical 204, 204′ and optical 205, 205′ waveforms to determine both (from the pressure-free measurement) and PTT2 (from the pressure dependent measurement). Typically the microprocessor determines both PTT1 and PTT2 by calculating the time difference between the peak of the QRS complex in the electrical waveform 204, 204′ and the foot (i.e. onset) of the optical waveform 205, 205′.
  • The approach described herein is based on the realization that an applied pressure (indicated by arrow 207) during the pressure-dependent measurement affects blood flow (indicated by arrows 203, 203′) in the underlying artery 202, 202′. Specifically, the applied pressure has no affect on either PTT2 or AMP2 when it is less than a diastolic pressure within the artery 202, 202′. When the applied pressure 207 reaches the diastolic pressure it begins to compress the artery, thus reducing blood flow and the effective internal pressure. This causes PTT2 to systematically increase relative to PTT1, and AMP2 to systematically decrease relative to AMP1. PTT2 increases and AMP2 decreases (typically in a linear maimer) as the applied pressure 207 approaches the systolic blood pressure within the artery 202, 202′. When the applied pressure 207 reaches the systolic blood pressure, AMP2 is completely eliminated and PTT2 consequently becomes immeasurable.
  • FIG. 9 illustrates the above-mentioned measurement in more detail. During a measurement the patient's heart 248 generates electrical impulses that pass through the body near the speed of light. These impulses accompany each heart heat, which then generates a pressure wave that propagates through the patient's vasculature at a significantly slower speed immediately after the heartbeat, the pressure wave leaves the heart 248 and aorta 249, passes through the subclavian artery 250, to the brachial artery 244, and from there through the radial and ulnar arteries 245 to smaller arteries in the patient's fingers. Three disposable electrodes located on the patient's chest measure unique electrical signals which pass to an amplifier/filter circuit within the body sensor. As described above, these electrodes attach to the patient's chest in a 1-vector ‘Einthoven's triangle’ configuration to measure unique electrical signals. Within the body sensor, the signals are processed using the amplifier/filter circuit to deter an analog electrical signal, which is digitized with an analog-to-digital converter to form the electrical waveform and then stored in memory. The optical sensor typically includes an optical module featuring an integrated photodetector, amplifier, and pair of light sources operating near 570 nm+/−10 nm. This wavelength is selected because it is particularly sensitive to volumetric absorbance changes in an underlying artery for a wide variety of skin types when deployed in a reflection-mode geometry. The optical sensor detects reflected radiation, which is further processed with a second amplifier/filter circuit within the body sensor. This results in the optical waveform, which, as described above, includes a series of pulses, each corresponding to an individual heartbeat.
  • During the composite technique, the same optical and electrical sensors are used during the pressure-dependent and pressure-free measurements to measure sipals from the patient 210. Optical 213 a, 213 b and electrical 212 a, 212 b waveforms from these measurements are shown in the graphs 211 a, 211 b in the figure. In the top graph showing the pressure-dependent measurement pressure gradually decreases with time.
  • Each pulse in the optical waveforms 213 a, 213 b from both measurements corresponds to an individual heartbeat, and represents a volumetric absorbance change in an underlying artery caused by the propagating pressure pulse. Likewise, the electrical waveforms 212 a, 212 b from each measurement feature a series of sharp, ‘QRS’ complexes corresponding to each heartbeat. As described above, pressure has a strong impact on amplitudes of pulses in the optical waveform 213 a during the pressure dependent measurement, but has no impact on the amplitudes of QRS complexes in the corresponding electrical waveform 212 a. These waveforms are processed as described below to determine blood pressure.
  • FIG. 10 shows, in more detail, graphs of the time-dependent pressure 221, optical 222, and electrical 223 waveforms measured during the pressure-dependent measurement. FIGS. 11A and 11B show, respectively, how PTT and the optical pulse amplitude determined from the optical 222 and electrical 223 waveforms vary with applied pressure for a typical patient. Pulses in the optical waveform 222 have no amplitude when the applied pressure is greater than systolic pressure (indicated by the dashed line 219) in the underlying artery. The pulses begin to appear when the applied pressure is equivalent to systolic blood pressure. Their amplitude increases, and their PTT decreases, as applied pressure decreases. These trends continue until diastolic pressure is reached. At this point, the amplitude of the pulses and the associated PTT values are relatively constant. QRS complexes in electrical waveform 223 are unaffected by the applied pressure.
  • During an actual pressure-dependent measurement, the body sensor collects data like that shown in FIGS. 11A and 11B, for an individual patient. A conventional peak-detecting algorithm running on the microprocessor in the body sensor detects the onset of the optical pulse amplitude, shown in FIG. 11B, to make a direct measurement of systolic blood pressure. Alternatively, a ‘fitting’ algorithm can model the systematic decrease in pulse amplitude with applied pressure with a mathematical function (e.g. a linear function) to estimate systolic blood pressure.
  • Similarly, for a given patient, the microprocessor analyzes the variation between applied pressure and PTT, shown graphically in FIG. 11A, to estimate the relationship between blood pressure and PTT. As shown in Equation 3, below, this relationship is best described with a mathematical model that first estimates how the patient's ‘effective’ mean arterial blood pressure (MAP*(P)) varies with applied pressure (Papplied). The model assumes that pressure applied by the armband occludes the patient's brachial artery, and thus temporarily decreases blood flow. This, in turn, increases blood pressure directly underneath the armband, and reduces blood pressure in the downstream radial, ulnar, and finger arteries. The net effect is a temporary, pressure-dependent reduction in the patient's mean arterial blood pressure (MAP), indicated in equation 1 as AMAP(P), during the pressure-dependent measurement. An empirically determined factor (F) accounts for the ratio between the region of increased blood pressure (underneath the armband; approximately 10 cm) and the larger region of decreased blood pressure (the length of the arm downstream from the armband; approximately 50 cm). F is typically between 0.6 and 0.9, and is preprogrammed into the algorithm prior to measurement.)

  • ΔMAP(P)=F*(P applied −DIA)

  • MAP*(P)=MAP−ΔMAP(P)
  • Using Equation 3, paired values of PTT and MAP*(P) are determined for each heartbeat as the applied pressure increases from the diastolic pressure to mean arterial pressure. This approach yields multiple data points during a single pressure-dependent measurement that can then be fit with a mathematical function (e.g. a linear function) relating PTT to mean arterial pressure. Typically these parameters are inversely related, i.e. PTT gets shorter and blood pressure increases. In typical embodiments, therefore, an inverse linear relationship determined during the pressure-dependent measurement is then used during subsequent pressure-free measurements to convert the measured PTT into blood pressure values.
  • In Equation 3, the values for diastolic blood pressure (DIA) and mean arterial pressure (MAP) are determined with an oscillometric blood pressure measurement during inflation. Systolic blood pressure (SYS) can either be determined indirectly during the oscillometric blood pressure measurement, or directly using the above-described method involving the pulse amplitude in the optical waveform. From these values, the SYS/MAP and DIA/MAP ratios can be determined. These ratios are typically constant for a given patient over a range of blood pressures. They can be used during the pressure-free measurements, along with the PTT-dependent mean arterial pressure, to determine systolic and diastolic blood pressures.
  • The oscillometric blood pressure measurement analyzes the pressure waveform (221 in FIG. 10) that is measured by the armband, Performing this measurement during inflation expedites the measurement and increases patient comfort. In contrast, most conventional cuff-based systems using the oscillometric technique analyze their pressure waveform during deflation, resulting in a measurement that is roughly 4 times longer than the composite technique's pressure-dependent measurement. Inflation-based measurements are possible because of the composite technique's relatively slow inflation speed (typically 5-10 mmHg/second) and the high sensitivity of the pressure sensor used within the body sensor. Moreover, measurements made during inflation can be immediately terminated once systolic blood pressure is calculated. In contrast, conventional cuff-based measurements made during deflation typically apply a pressure that far exceeds the patient's systolic blood pressure; pressure within the cuff then slowly bleeds down below the diastolic pressure to complete the measurement.
  • Other embodiments are also within the scope of the invention. For example, other properties of the optical waveform, such as the width, rise time, fall time, dichrotic notch, general shape, or any other feature that indicates arterial properties, can be used to estimate the stiffness of the patient's arteries and used along with PTT to improve the accuracy of the blood pressure measurement.
  • In other embodiments, software configurations other than those described above can be run on the bedside device to give it a PDA-like functionality. These include, for example, Micro COS®, Linux®, Microsoft Windows®, embOS, VxWorks, SymhianOS, QNX, OSE, BSD and its variants, FreeDOS, FreeRTOX, LynxOS, or eCOS and other embedded operating systems. The device can also run a software configuration that allows it to receive and send voice calls, text messages, or video streams received through the Internet or from the nation-wide wireless network it connects to. A bar-code scanner can also be incorporated into the device to capture patient or medical professional identification information, or other such labeling. This information, for example, can be used to communicate with a patient in a hospital or at home. In other embodiments, the device can connect to an Internet-accessible website to download content, e.g., calibrations, software updates, text messages, and information describing medications, from an associated website. As described above, the device can connect to the website using both wired (e.g., USB port) or wireless (e.g., short or long-range wireless transceivers) means. In still other embodiments, ‘alert’ values corresponding to vital signs and the pager or cell phone number of a caregiver can be programmed into the device using its graphical user interface. If a patient's vital signs meet an alert criteria, software on the device can send a wireless ‘page’ to the caregiver, thereby alerting them to the patient's condition. For additional patient safety, a confirmation scheme can be implemented that alerts other individuals or systems until acknowledgment of the alert is received.

Claims (7)

1-20. (canceled)
21. A method for measuring a patient's blood pressure with a blood pressure monitor, the method, comprising:
determining a vascular index (VI) according to the equation VI=(A1+[(b-c-d-e)/a])/A2, where A1 is 1.515, A2 is 0.023, and a, b, c, d, and e are fiduciary features obtained from a time-dependent plethysmography signal measured using an optical sensor disposed on the patient's finger;
determining a first systolic blood pressure using a pulse transit time (PTT) obtained from the first time-dependent plethysmography signal and a time dependent electrical waveform measured using an ECG sensor disposed on the patient's chest;
determining a second systolic blood pressure using the PTT, the VI, and the patient's age.
22. The method of claim 21, wherein a, b, c, d, and e are obtained from the time-dependent plethysmography signal by calculating a second derivative of the time-dependent plethysmography signal and identifying a, b, c, d, and e in the second derivative waveform.
23. The method of claim 21, further comprising determining arterial stiffness for the patient.
24. The method of claim 21, wherein the PTT is obtained by analyzing a first time-dependent feature from the time dependent electrical waveform or a derivative thereof, and a second time-dependent feature from the time-dependent plethysmography signal or a derivative thereof.
25. The method of claim 21, wherein the first time-dependent feature comprises a peak corresponding to a QRS complex.
26. The method of claim 25, wherein the second time-dependent feature comprises a foot in the time-dependent plethysmography signal or a derivative thereof.
US14/072,305 2007-06-12 2013-11-05 Vital sign monitor for cufflessly measuring blood pressure using a pulse transit time corrected for vascular index Abandoned US20140142445A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US14/072,305 US20140142445A1 (en) 2007-06-12 2013-11-05 Vital sign monitor for cufflessly measuring blood pressure using a pulse transit time corrected for vascular index

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94352307P 2007-06-12 2007-06-12
US12/138,199 US8574161B2 (en) 2007-06-12 2008-06-12 Vital sign monitor for cufflessly measuring blood pressure using a pulse transit time corrected for vascular index
US14/072,305 US20140142445A1 (en) 2007-06-12 2013-11-05 Vital sign monitor for cufflessly measuring blood pressure using a pulse transit time corrected for vascular index

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US12/138,199 Continuation US8574161B2 (en) 2007-06-12 2008-06-12 Vital sign monitor for cufflessly measuring blood pressure using a pulse transit time corrected for vascular index

Publications (1)

Publication Number Publication Date
US20140142445A1 true US20140142445A1 (en) 2014-05-22

Family

ID=40130222

Family Applications (2)

Application Number Title Priority Date Filing Date
US12/138,199 Active 2031-06-30 US8574161B2 (en) 2007-06-12 2008-06-12 Vital sign monitor for cufflessly measuring blood pressure using a pulse transit time corrected for vascular index
US14/072,305 Abandoned US20140142445A1 (en) 2007-06-12 2013-11-05 Vital sign monitor for cufflessly measuring blood pressure using a pulse transit time corrected for vascular index

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US12/138,199 Active 2031-06-30 US8574161B2 (en) 2007-06-12 2008-06-12 Vital sign monitor for cufflessly measuring blood pressure using a pulse transit time corrected for vascular index

Country Status (2)

Country Link
US (2) US8574161B2 (en)
WO (1) WO2008154647A1 (en)

Cited By (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USD788312S1 (en) 2012-02-09 2017-05-30 Masimo Corporation Wireless patient monitoring device
US9814388B2 (en) 2016-02-11 2017-11-14 General Electric Company Wireless patient monitoring system and method
US9883800B2 (en) 2016-02-11 2018-02-06 General Electric Company Wireless patient monitoring system and method
US20180146865A1 (en) * 2015-05-29 2018-05-31 Cis Forschungsinstitut Fuer Mikrosensorik Gmbh Method and device for ascertaining a blood pressure curve
IT201700031915A1 (en) * 2017-03-23 2018-09-23 Univ Degli Studi Di Modena E Reggio Emilia SYSTEM AND METHOD FOR THE DETECTION OF PHYSIOLOGICAL VITAMINAL PARAMETERS OF A SUBJECT.
US10098558B2 (en) 2016-04-25 2018-10-16 General Electric Company Wireless patient monitoring system and method
US10226187B2 (en) 2015-08-31 2019-03-12 Masimo Corporation Patient-worn wireless physiological sensor
US10307111B2 (en) 2012-02-09 2019-06-04 Masimo Corporation Patient position detection system
US10470692B2 (en) 2015-06-12 2019-11-12 ChroniSense Medical Ltd. System for performing pulse oximetry
US10617302B2 (en) 2016-07-07 2020-04-14 Masimo Corporation Wearable pulse oximeter and respiration monitor
US10687742B2 (en) 2015-06-12 2020-06-23 ChroniSense Medical Ltd. Using invariant factors for pulse oximetry
WO2020144397A1 (en) * 2019-01-09 2020-07-16 Turun Yliopisto An apparatus for measuring functionality of an arterial system
US10772571B2 (en) 2016-11-15 2020-09-15 Welch Allyn, Inc. Method and systems for correcting for arterial compliance in a blood pressure assessment
US10806933B2 (en) 2017-09-06 2020-10-20 General Electric Company Patient monitoring systems and methods that detect interference with pacemaker
US10952638B2 (en) 2015-06-12 2021-03-23 ChroniSense Medical Ltd. System and method for monitoring respiratory rate and oxygen saturation
US11000235B2 (en) 2016-03-14 2021-05-11 ChroniSense Medical Ltd. Monitoring procedure for early warning of cardiac episodes
US11076777B2 (en) 2016-10-13 2021-08-03 Masimo Corporation Systems and methods for monitoring orientation to reduce pressure ulcer formation
EP3895606A1 (en) * 2016-07-20 2021-10-20 Samsung Electronics Co., Ltd. Apparatus and method for extracting feature of bio-signal, and apparatus for detecting bio information
US11160461B2 (en) 2015-06-12 2021-11-02 ChroniSense Medical Ltd. Blood pressure measurement using a wearable device
US11160459B2 (en) 2015-06-12 2021-11-02 ChroniSense Medical Ltd. Monitoring health status of people suffering from chronic diseases
US11298086B2 (en) 2018-10-05 2022-04-12 Samsung Electronics Co., Ltd. Apparatus and method for estimating blood pressure
US11331508B1 (en) * 2018-04-25 2022-05-17 West Affum Holdings Corp. Wearable cardioverter defibrillator with a non-invasive blood pressure monitor
US11464457B2 (en) 2015-06-12 2022-10-11 ChroniSense Medical Ltd. Determining an early warning score based on wearable device measurements
USD974193S1 (en) 2020-07-27 2023-01-03 Masimo Corporation Wearable temperature measurement device
USD980091S1 (en) 2020-07-27 2023-03-07 Masimo Corporation Wearable temperature measurement device
WO2023089130A1 (en) * 2021-11-19 2023-05-25 Leman Micro Devices Sa Measurement of parameters related to the health of a user
US11712190B2 (en) 2015-06-12 2023-08-01 ChroniSense Medical Ltd. Wearable device electrocardiogram
USD1000975S1 (en) 2021-09-22 2023-10-10 Masimo Corporation Wearable temperature measurement device
US11801016B2 (en) 2019-12-30 2023-10-31 Hemocept Inc. System and method of assessing intra-arterial fluid volume using intelligent pulse averaging with integrated EKG and PPG sensors
USD1022729S1 (en) 2022-12-20 2024-04-16 Masimo Corporation Wearable temperature measurement device

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008085603A1 (en) * 2007-01-10 2008-07-17 Camillo Ricordi Mobile emergency alert system
US8506480B2 (en) * 2007-07-11 2013-08-13 Sotera Wireless, Inc. Device for determining respiratory rate and other vital signs
WO2008154647A1 (en) * 2007-06-12 2008-12-18 Triage Wireless, Inc. Vital sign monitor for cufflessly measuring blood pressure corrected for vascular index
WO2008154643A1 (en) * 2007-06-12 2008-12-18 Triage Wireless, Inc. Vital sign monitor for measuring blood pressure using optical, electrical, and pressure waveforms
US20100130875A1 (en) * 2008-06-18 2010-05-27 Triage Wireless, Inc. Body-worn system for measuring blood pressure
US20080319327A1 (en) * 2007-06-25 2008-12-25 Triage Wireless, Inc. Body-worn sensor featuring a low-power processor and multi-sensor array for measuring blood pressure
US20090118628A1 (en) * 2007-11-01 2009-05-07 Triage Wireless, Inc. System for measuring blood pressure featuring a blood pressure cuff comprising size information
US20090243878A1 (en) * 2008-03-31 2009-10-01 Camillo Ricordi Radio frequency transmitter and receiver system and apparatus
US20110066044A1 (en) 2009-09-15 2011-03-17 Jim Moon Body-worn vital sign monitor
EP2515744A2 (en) * 2009-12-23 2012-10-31 DELTA, Dansk Elektronik, Lys & Akustik A monitoring device
US20120094600A1 (en) 2010-10-19 2012-04-19 Welch Allyn, Inc. Platform for patient monitoring
WO2013090850A1 (en) 2011-12-14 2013-06-20 California Institute Of Technology Noninvasive systems for blood pressure measurement in arteries
JP6162143B2 (en) 2011-12-22 2017-07-12 カリフォルニア インスティチュート オブ テクノロジー Natural frequency hemodynamic waveform analysis
CN103417221B (en) * 2012-05-18 2015-08-19 财团法人工业技术研究院 Blood parameter measuring device and blood parameter measuring method
US9504391B2 (en) 2013-03-04 2016-11-29 Microsoft Technology Licensing, Llc Determining pulse transit time non-invasively using handheld devices
US10271233B2 (en) 2013-03-15 2019-04-23 DGS Global Systems, Inc. Systems, methods, and devices for automatic signal detection with temporal feature extraction within a spectrum
US9622041B2 (en) * 2013-03-15 2017-04-11 DGS Global Systems, Inc. Systems, methods, and devices for electronic spectrum management
US10231206B2 (en) 2013-03-15 2019-03-12 DGS Global Systems, Inc. Systems, methods, and devices for electronic spectrum management for identifying signal-emitting devices
US10237770B2 (en) 2013-03-15 2019-03-19 DGS Global Systems, Inc. Systems, methods, and devices having databases and automated reports for electronic spectrum management
US11646918B2 (en) 2013-03-15 2023-05-09 Digital Global Systems, Inc. Systems, methods, and devices for electronic spectrum management for identifying open space
FI124971B (en) * 2013-03-22 2015-04-15 Murata Manufacturing Co Blood pressure measuring device and blood pressure calibration method
US10610166B2 (en) 2013-07-08 2020-04-07 Edwards Lifesciences Corporation Determination of a hemodynamic parameter
WO2015058155A1 (en) 2013-10-18 2015-04-23 California Institute Of Technology Intrinsic frequency analysis for left ventricle ejection fraction or stroke volume determination
MX2016009335A (en) 2014-01-21 2017-02-02 California Inst Of Techn Portable electronic hemodynamic sensor systems.
US20170079533A1 (en) * 2014-05-01 2017-03-23 Medici Technologies, LLC Diabetes and Hypertension Screening by Assessment of Arterial Stiffness and Autonomic Function
US9408541B2 (en) 2014-08-04 2016-08-09 Yamil Kuri System and method for determining arterial compliance and stiffness
WO2016029196A1 (en) * 2014-08-22 2016-02-25 Sotera Wirless, Inc. System for calibrating a blood pressure measurement based on vascular transit of a pulse wave
CN104382571B (en) * 2014-10-28 2017-06-16 深圳市维亿魄科技有限公司 A kind of measurement blood pressure method and device based on radial artery pulse wave conduction time
RU2601697C2 (en) * 2014-10-31 2016-11-10 Общество с ограниченной ответственностью "ХЕЛФИ-СТИЛЬ" Device and method for measuring human arterial pressure value
CN104644147B (en) * 2014-12-26 2016-08-24 吉训明 A kind of ischemic preconditioning therapeutic instrument and judging application and the method for vascular health situation
CN204515353U (en) 2015-03-31 2015-07-29 深圳市长桑技术有限公司 A kind of intelligent watch
WO2016107607A1 (en) 2015-01-04 2016-07-07 Vita-Course Technologies Co.,Ltd System and method for health monitoring
US10383518B2 (en) * 2015-03-31 2019-08-20 Midmark Corporation Electronic ecosystem for medical examination room
US11213212B2 (en) * 2015-12-07 2022-01-04 Samsung Electronics Co., Ltd. Apparatus for measuring blood pressure, and method for measuring blood pressure by using same
KR102584577B1 (en) * 2015-12-07 2023-10-05 삼성전자주식회사 Blood presure measurement apparatus and blood presure measuring method using the same
US10004460B2 (en) 2016-01-05 2018-06-26 Tosense, Inc. Floormat physiological sensor
US10258286B2 (en) 2016-01-05 2019-04-16 Tosense, Inc. Floormat physiological sensor
US10188349B2 (en) 2016-01-05 2019-01-29 Tosense, Inc. Floormat physiological sensor
US20170188973A1 (en) * 2016-01-05 2017-07-06 Tosense, Inc. Physiological monitoring system featuring floormat and wired handheld sensor
US10182729B2 (en) 2016-08-31 2019-01-22 Medtronics, Inc. Systems and methods for monitoring hemodynamic status
US10700794B2 (en) * 2017-01-23 2020-06-30 Digital Global Systems, Inc. Systems, methods, and devices for automatic signal detection based on power distribution by frequency over time within an electromagnetic spectrum
US10459020B2 (en) 2017-01-23 2019-10-29 DGS Global Systems, Inc. Systems, methods, and devices for automatic signal detection based on power distribution by frequency over time within a spectrum
US10529241B2 (en) 2017-01-23 2020-01-07 Digital Global Systems, Inc. Unmanned vehicle recognition and threat management
US10498951B2 (en) 2017-01-23 2019-12-03 Digital Global Systems, Inc. Systems, methods, and devices for unmanned vehicle detection
TWI685326B (en) * 2018-06-01 2020-02-21 華碩電腦股份有限公司 Wearable blood pressure detecting device and detecting method thereof
CN109044302A (en) * 2018-07-03 2018-12-21 京东方科技集团股份有限公司 Measure device, electronic equipment and the computer readable storage medium of blood pressure
US10943461B2 (en) 2018-08-24 2021-03-09 Digital Global Systems, Inc. Systems, methods, and devices for automatic signal detection based on power distribution by frequency over time
US11642034B2 (en) 2018-10-12 2023-05-09 ViviPulse, LLC Blood pressure measuring device and method
CN110265150A (en) * 2019-07-30 2019-09-20 河北工程大学 Blood pressure calculates method for establishing model and wearable monitoring device and blood pressure measuring method
WO2022182956A1 (en) * 2021-02-26 2022-09-01 University Of Washington Remote monitoring of oxygenation status and blood pulsation within skin tissue

Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6623434B2 (en) * 1990-12-28 2003-09-23 Hypertension Diagnostics, Inc. Method and instrument to measure vascular impedance
US6740045B2 (en) * 2001-04-19 2004-05-25 Seiko Epson Corporation Central blood pressure waveform estimation device and peripheral blood pressure waveform detection device
US6881190B2 (en) * 2002-03-01 2005-04-19 Colin Medical Technology Corporation Standard pulse-wave-propagation-velocity-related-value determining apparatus and pulse-wave-propagation-velocity-related-value obtaining apparatus
US20050222514A1 (en) * 2004-03-31 2005-10-06 Nihon Kohden Corporation Method and apparatus for measuring blood volume, and vital sign monitor using the same
US7179228B2 (en) * 2004-04-07 2007-02-20 Triage Wireless, Inc. Cuffless system for measuring blood pressure
US20080015451A1 (en) * 2006-07-13 2008-01-17 Hatib Feras S Method and Apparatus for Continuous Assessment of a Cardiovascular Parameter Using the Arterial Pulse Pressure Propagation Time and Waveform
US20080033305A1 (en) * 2006-07-13 2008-02-07 Hatib Feras S Method and apparatus for continuous assessment of a cardiovascular parameter using the arterial pulse pressure propagation time and waveform
US20080221461A1 (en) * 2007-03-05 2008-09-11 Triage Wireless, Inc. Vital sign monitor for cufflessly measuring blood pressure without using an external calibration
US20080319327A1 (en) * 2007-06-25 2008-12-25 Triage Wireless, Inc. Body-worn sensor featuring a low-power processor and multi-sensor array for measuring blood pressure
US7674231B2 (en) * 2005-08-22 2010-03-09 Massachusetts Institute Of Technology Wearable pulse wave velocity blood pressure sensor and methods of calibration thereof
US8419649B2 (en) * 2007-06-12 2013-04-16 Sotera Wireless, Inc. Vital sign monitor for measuring blood pressure using optical, electrical and pressure waveforms
US8535234B2 (en) * 2009-04-17 2013-09-17 Nihon Kohden Corporation Apparatus for measuring blood volume and method of evaluating result of measurement by apparatus for measuring blood volume
US8574161B2 (en) * 2007-06-12 2013-11-05 Sotera Wireless, Inc. Vital sign monitor for cufflessly measuring blood pressure using a pulse transit time corrected for vascular index
US8591428B2 (en) * 2009-04-17 2013-11-26 Nihon Kohden Corporation Method and apparatus for measuring blood volume
US8602997B2 (en) * 2007-06-12 2013-12-10 Sotera Wireless, Inc. Body-worn system for measuring continuous non-invasive blood pressure (cNIBP)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4653498A (en) * 1982-09-13 1987-03-31 Nellcor Incorporated Pulse oximeter monitor
US5316008A (en) * 1990-04-06 1994-05-31 Casio Computer Co., Ltd. Measurement of electrocardiographic wave and sphygmus
JP3318727B2 (en) * 1994-06-06 2002-08-26 日本光電工業株式会社 Pulse wave transit time sphygmomanometer
US5865755A (en) * 1996-10-11 1999-02-02 Dxtek, Inc. Method and apparatus for non-invasive, cuffless, continuous blood pressure determination
EP1195136B1 (en) * 2000-03-23 2008-10-29 Seiko Epson Corporation Biological information rating device
US20070185393A1 (en) * 2006-02-03 2007-08-09 Triage Wireless, Inc. System for measuring vital signs using an optical module featuring a green light source
US20080082004A1 (en) * 2006-09-08 2008-04-03 Triage Wireless, Inc. Blood pressure monitor
US20080221399A1 (en) * 2007-03-05 2008-09-11 Triage Wireless, Inc. Monitor for measuring vital signs and rendering video images

Patent Citations (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6623434B2 (en) * 1990-12-28 2003-09-23 Hypertension Diagnostics, Inc. Method and instrument to measure vascular impedance
US6740045B2 (en) * 2001-04-19 2004-05-25 Seiko Epson Corporation Central blood pressure waveform estimation device and peripheral blood pressure waveform detection device
US6881190B2 (en) * 2002-03-01 2005-04-19 Colin Medical Technology Corporation Standard pulse-wave-propagation-velocity-related-value determining apparatus and pulse-wave-propagation-velocity-related-value obtaining apparatus
US20050222514A1 (en) * 2004-03-31 2005-10-06 Nihon Kohden Corporation Method and apparatus for measuring blood volume, and vital sign monitor using the same
US7179228B2 (en) * 2004-04-07 2007-02-20 Triage Wireless, Inc. Cuffless system for measuring blood pressure
US7674231B2 (en) * 2005-08-22 2010-03-09 Massachusetts Institute Of Technology Wearable pulse wave velocity blood pressure sensor and methods of calibration thereof
US20080015451A1 (en) * 2006-07-13 2008-01-17 Hatib Feras S Method and Apparatus for Continuous Assessment of a Cardiovascular Parameter Using the Arterial Pulse Pressure Propagation Time and Waveform
US20080033305A1 (en) * 2006-07-13 2008-02-07 Hatib Feras S Method and apparatus for continuous assessment of a cardiovascular parameter using the arterial pulse pressure propagation time and waveform
US20080221461A1 (en) * 2007-03-05 2008-09-11 Triage Wireless, Inc. Vital sign monitor for cufflessly measuring blood pressure without using an external calibration
US8574161B2 (en) * 2007-06-12 2013-11-05 Sotera Wireless, Inc. Vital sign monitor for cufflessly measuring blood pressure using a pulse transit time corrected for vascular index
US8419649B2 (en) * 2007-06-12 2013-04-16 Sotera Wireless, Inc. Vital sign monitor for measuring blood pressure using optical, electrical and pressure waveforms
US8602997B2 (en) * 2007-06-12 2013-12-10 Sotera Wireless, Inc. Body-worn system for measuring continuous non-invasive blood pressure (cNIBP)
US8740802B2 (en) * 2007-06-12 2014-06-03 Sotera Wireless, Inc. Body-worn system for measuring continuous non-invasive blood pressure (cNIBP)
US8808188B2 (en) * 2007-06-12 2014-08-19 Sotera Wireless, Inc. Body-worn system for measuring continuous non-invasive blood pressure (cNIBP)
US9161700B2 (en) * 2007-06-12 2015-10-20 Sotera Wireless, Inc. Body-worn system for measuring continuous non-invasive blood pressure (cNIBP)
US9215986B2 (en) * 2007-06-12 2015-12-22 Sotera Wireless, Inc. Body-worn system for measuring continuous non-invasive blood pressure (cNIBP)
US20080319327A1 (en) * 2007-06-25 2008-12-25 Triage Wireless, Inc. Body-worn sensor featuring a low-power processor and multi-sensor array for measuring blood pressure
US8535234B2 (en) * 2009-04-17 2013-09-17 Nihon Kohden Corporation Apparatus for measuring blood volume and method of evaluating result of measurement by apparatus for measuring blood volume
US8591428B2 (en) * 2009-04-17 2013-11-26 Nihon Kohden Corporation Method and apparatus for measuring blood volume

Cited By (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USD788312S1 (en) 2012-02-09 2017-05-30 Masimo Corporation Wireless patient monitoring device
US11918353B2 (en) 2012-02-09 2024-03-05 Masimo Corporation Wireless patient monitoring device
US10188296B2 (en) 2012-02-09 2019-01-29 Masimo Corporation Wireless patient monitoring device
US11083397B2 (en) 2012-02-09 2021-08-10 Masimo Corporation Wireless patient monitoring device
US10149616B2 (en) 2012-02-09 2018-12-11 Masimo Corporation Wireless patient monitoring device
US10307111B2 (en) 2012-02-09 2019-06-04 Masimo Corporation Patient position detection system
US20180146865A1 (en) * 2015-05-29 2018-05-31 Cis Forschungsinstitut Fuer Mikrosensorik Gmbh Method and device for ascertaining a blood pressure curve
US10362945B2 (en) * 2015-05-29 2019-07-30 Cis Forschungsinstitut Fuer Mikrosensorik Gmbh Method and device for ascertaining a blood pressure curve
US11712190B2 (en) 2015-06-12 2023-08-01 ChroniSense Medical Ltd. Wearable device electrocardiogram
US11931155B2 (en) 2015-06-12 2024-03-19 ChroniSense Medical Ltd. Wearable wrist device electrocardiogram
US11464457B2 (en) 2015-06-12 2022-10-11 ChroniSense Medical Ltd. Determining an early warning score based on wearable device measurements
US11571139B2 (en) 2015-06-12 2023-02-07 ChroniSense Medical Ltd. Wearable system and method for measuring oxygen saturation
US10687742B2 (en) 2015-06-12 2020-06-23 ChroniSense Medical Ltd. Using invariant factors for pulse oximetry
US11160461B2 (en) 2015-06-12 2021-11-02 ChroniSense Medical Ltd. Blood pressure measurement using a wearable device
US10470692B2 (en) 2015-06-12 2019-11-12 ChroniSense Medical Ltd. System for performing pulse oximetry
US11160459B2 (en) 2015-06-12 2021-11-02 ChroniSense Medical Ltd. Monitoring health status of people suffering from chronic diseases
US10952638B2 (en) 2015-06-12 2021-03-23 ChroniSense Medical Ltd. System and method for monitoring respiratory rate and oxygen saturation
US10383527B2 (en) 2015-08-31 2019-08-20 Masimo Corporation Wireless patient monitoring systems and methods
US11089963B2 (en) 2015-08-31 2021-08-17 Masimo Corporation Systems and methods for patient fall detection
US10736518B2 (en) 2015-08-31 2020-08-11 Masimo Corporation Systems and methods to monitor repositioning of a patient
US11576582B2 (en) 2015-08-31 2023-02-14 Masimo Corporation Patient-worn wireless physiological sensor
US10226187B2 (en) 2015-08-31 2019-03-12 Masimo Corporation Patient-worn wireless physiological sensor
US10448844B2 (en) 2015-08-31 2019-10-22 Masimo Corporation Systems and methods for patient fall detection
US9883800B2 (en) 2016-02-11 2018-02-06 General Electric Company Wireless patient monitoring system and method
US10517478B2 (en) 2016-02-11 2019-12-31 General Electric Company Wireless patient monitoring system and method
US9814388B2 (en) 2016-02-11 2017-11-14 General Electric Company Wireless patient monitoring system and method
US10939820B2 (en) 2016-02-11 2021-03-09 General Electric Company Wireless patient monitoring system and method
US11000235B2 (en) 2016-03-14 2021-05-11 ChroniSense Medical Ltd. Monitoring procedure for early warning of cardiac episodes
US10098558B2 (en) 2016-04-25 2018-10-16 General Electric Company Wireless patient monitoring system and method
US10617302B2 (en) 2016-07-07 2020-04-14 Masimo Corporation Wearable pulse oximeter and respiration monitor
US11202571B2 (en) 2016-07-07 2021-12-21 Masimo Corporation Wearable pulse oximeter and respiration monitor
EP3895606A1 (en) * 2016-07-20 2021-10-20 Samsung Electronics Co., Ltd. Apparatus and method for extracting feature of bio-signal, and apparatus for detecting bio information
US11076777B2 (en) 2016-10-13 2021-08-03 Masimo Corporation Systems and methods for monitoring orientation to reduce pressure ulcer formation
US10772571B2 (en) 2016-11-15 2020-09-15 Welch Allyn, Inc. Method and systems for correcting for arterial compliance in a blood pressure assessment
IT201700031915A1 (en) * 2017-03-23 2018-09-23 Univ Degli Studi Di Modena E Reggio Emilia SYSTEM AND METHOD FOR THE DETECTION OF PHYSIOLOGICAL VITAMINAL PARAMETERS OF A SUBJECT.
WO2018172958A1 (en) * 2017-03-23 2018-09-27 Universita' Degli Studi Di Modena E Reggio Emilia System and method for detecting vital physiological parameters of a subject
US10806933B2 (en) 2017-09-06 2020-10-20 General Electric Company Patient monitoring systems and methods that detect interference with pacemaker
US11331508B1 (en) * 2018-04-25 2022-05-17 West Affum Holdings Corp. Wearable cardioverter defibrillator with a non-invasive blood pressure monitor
US11298086B2 (en) 2018-10-05 2022-04-12 Samsung Electronics Co., Ltd. Apparatus and method for estimating blood pressure
US11744526B2 (en) 2018-10-05 2023-09-05 Samsung Electronics Co., Ltd. Apparatus and method for estimating blood pressure
WO2020144397A1 (en) * 2019-01-09 2020-07-16 Turun Yliopisto An apparatus for measuring functionality of an arterial system
US11801016B2 (en) 2019-12-30 2023-10-31 Hemocept Inc. System and method of assessing intra-arterial fluid volume using intelligent pulse averaging with integrated EKG and PPG sensors
US11896405B2 (en) 2019-12-30 2024-02-13 Hemocept Inc. System and method of measuring venous oxygen saturation using intelligent pulse averaging with integrated EKG and PPG sensors
USD980091S1 (en) 2020-07-27 2023-03-07 Masimo Corporation Wearable temperature measurement device
USD974193S1 (en) 2020-07-27 2023-01-03 Masimo Corporation Wearable temperature measurement device
USD1000975S1 (en) 2021-09-22 2023-10-10 Masimo Corporation Wearable temperature measurement device
WO2023089130A1 (en) * 2021-11-19 2023-05-25 Leman Micro Devices Sa Measurement of parameters related to the health of a user
USD1022729S1 (en) 2022-12-20 2024-04-16 Masimo Corporation Wearable temperature measurement device

Also Published As

Publication number Publication date
US20090018422A1 (en) 2009-01-15
WO2008154647A1 (en) 2008-12-18
US8574161B2 (en) 2013-11-05

Similar Documents

Publication Publication Date Title
US8574161B2 (en) Vital sign monitor for cufflessly measuring blood pressure using a pulse transit time corrected for vascular index
US8419649B2 (en) Vital sign monitor for measuring blood pressure using optical, electrical and pressure waveforms
US8506480B2 (en) Device for determining respiratory rate and other vital signs
US20080221461A1 (en) Vital sign monitor for cufflessly measuring blood pressure without using an external calibration
US8602997B2 (en) Body-worn system for measuring continuous non-invasive blood pressure (cNIBP)
US7179228B2 (en) Cuffless system for measuring blood pressure
US20100130875A1 (en) Body-worn system for measuring blood pressure
US11330988B2 (en) Body-worn system for measuring continuous non-invasive blood pressure (cNIBP)
US20060084878A1 (en) Personal computer-based vital signs monitor
US11064918B2 (en) Patch-based physiological sensor
US11202578B2 (en) Patch-based physiological sensor
KR102272019B1 (en) Blood Pressure Meter And Method For Measuring Blood Pressure Using The Same
US11116410B2 (en) Patch-based physiological sensor
US11096590B2 (en) Patch-based physiological sensor
US10842392B2 (en) Patch-based physiological sensor

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION